WO2010132899A1 - Bioabsorbable polymeric compositions and medical devices - Google Patents

Abstract

The present invention discloses a stent comprising a blend formed from a polymer. The polymer comprises poly-L-lactide, poly-D-lactide or mixtures thereof and a copolymer moiety comprising poly-L-lactide or poly-D-lactide linked with epsilon-caprolactone or trimethylcarbonate. The poly-L-lactide or poly-D-lactide sequence in the copolymer moiety is random with respect to the distribution of epsilon-caprolactone or trimethylcarbonate and the copolymer moiety molecular weight ranges from about 1.2 IV to about 4.8 IV. The polymere blend may have a wide-angle X-ray scattering (W AXS) 2-theta values of ranging from about 1 to about 35. The properties of the bioabsorbable polymers allow for both crimping and expansion of the stent. The crystal properties of the bioabsorbable polymers may change during crimping and/or expansion allowing for improved mechanical properties such as tensile strength and slower degradation kinetics

Description

BIOABSORBABLE POLYMERIC COMPOSITIONS AND MEDICAL DEVICES

CROSS-REFERENCE TO RELATED APPLICATION

This application is a continuation-in-part of U.S. Application Ser. No. 12/578,432, filed on October 13, 2009; U.S. Application Ser. No. 12/576,965, filed on October 9, 2009; U.S. Application Ser. No. 12/507,663, filed on July 22, 2009; U.S. Application Ser. No. 11/875,887, filed on October 20, 2007; U.S. Application Ser. No. 11/875,892, filed on October 20, 2007; U.S. Application Ser. No. 11/781,234, filed on July 20, 2007; and U.S. Application Ser. No. 11/781,232, filed on July 20, 2007, all of which are hereby incorporated by reference. This application also claims the benefit of U.S. Provisional Application No. 61/178,878, filed on May 15, 2009 which is hereby incorporated by reference.

BACKGROUND OF THE INVENTION

Although the use of bioabsorbable polymers is well known, the development of effective bioabsorbable polymers for medical devices that undergo high stress such as exposure to the pressures of arterial contraction and blood flow represents a major on-going challenge for biomedical scientists. Thus, the development of a bioabsorbable stent that would retain its shape, yet degrade within a reasonable time period without producing a drastic immune response remains an unsolved problem. Bioabsorbable polymers comprise a wide range of different polymers. Most typically bioabsorbable polymers are formed from aliphatic polyesters based on a lactide backbone such as, poly L-lactide, poly D-Lactide, poly D,L-Lactide, meso lactide, glycolides, homopolymers, or heteropolymers formed in copolymer moieties with co-monomers such as, trimethylene carbonate (TMC) or ε-caprolactone (ECL). U.S. Patent No. 6,706,854; U.S. Patent No. 6,607,548; EP 0401844; WO 2006/111578; and, Jeon et al. Synthesis and Characterization of Poly (L-lactide) - Poly (ε-caprolactone) Multiblock Copolymers. Macromolecules 2003: 36, 5585 - 5592. Moreover, the use of biodegradable materials with a medical device such as a stent can help to overcome some of the traumatic stress injuries, such as restenosis, that is commonly associated with metal stents. The synthesis of polylactides is well understood chemically (see, for example, http://www.puracbiomatcrials.corα^/purac bio com, October 10, 2009/; http://\vwwA^oehringcr-ingclhcimxonL^/corporatc/ic/pharmachern/products/rcsomer.asp, October 10, 2009). Once a polymer is formed, it can be blended together with other polymers or pharmaceutical agents, extruded or molded and then, subjected to temperature changes or physical stressJThese treatments alter the final crystalline structure resulting in a composite or hybrid material that has unique physical characteristics, including both crystal structures as well as mechanical properties.

The bioabsorbable polymer blends typically include a base polymer (which itself may be a blend) and an additive polymer; the additive polymer imparts additional molecular free volume to the base polymer allowing for sufficient molecular motion of the polymers so that under physiological conditions, re-crystallization can occur. In addition, increased molecular free volume also allows for increased water uptake which facilitates bulk degradation kinetics. This property allows for incorporation of temperature sensitive, pharmaceutically active agents into the blend.

Because inflammation which ultimately results in restenosis represents a major issue with the introduction of any "foreign" medical device such as a metal stent, it is also important to develop polymer blends that will not stimulate the immune system to the extent observed with other medical devices. For example, the enhanced hydrophilicity of certain polymer blends reduces activation of the complement system, (see, Dong et. al, J. of Biomedical Materials Research, part A, DOI 10.1002, 2006). Thus, developing a polymer blend that will produce a structurally strong medical device such as stent which will remain for a defined period within the body and then degrade without generating a massive immune response is critical.

SUMMARY OF THE INVENTION

The present invention provides for a stent formed from a blend of polymers, comprising a polymer formed from poly-L-lactide, poly-D-lactide or mixtures thereof and a copolymer moiety comprising poly-L-lactide or poly-D-lactide linked with ε-caprolactone or trimethylcarbonate. The copolymer moiety comprises poly-L-lactide or poly-D-lactide linked with ε-caprolactone or trimethylcarbonate wherein, the poly-L-lactide or poly-D-lactide sequence in the copolymer moiety is random with respect to the distribution of ε-caprolactone or trimethylcarbonate. The crystalline structure of the polymer blend shows a wide-angle X- ray scattering (WAXS) that exhibits 2Θ values of about 16.48 and about 18.76. In certain embodiments, the copolymer moiety is poly-L-lactide or poly-D-lactide linked with ε- caprolactone.

In one embodiment, the stent can be made from a blend having about 20% (w/w) to about 45% (w/w) poly-L-lactide, about 30% (w/w) to about 50% (w/w) poly-D-lactide and about 10% (w/w) to about 35% (w/w) poly L-lactide-co-TMC (about 60/40 mole/mole to about 80/20 mole/mole, with about 70/30 mole/mole being one embodiment) or poly-L- lactide- ε-caprolactone; the poly-L-lactide or poly-D-lactide ranges from about 20% (w/w) to about 95% (w/w); from about 50% (w/w) to about 95% (w/w); from about 60% (w/w) to about 95% (w/w); or from about 70% (w/w) to about 80% (w/w).

In another embodiment, the stent comprises a blend formed from a polymer formed from poly-L-lactide, poly-D-lactide or mixtures thereof and a copolymer moiety comprising poly-L-lactide or poly-D-lactide linked with ε-caprolactone or trimethylcarbonate. The poly- L-lactide or poly-D-lactide sequence in the copolymer moiety is random with respect to the distribution of ε-caprolactone or trimethylcarbonate and there is at least about 95% (w/w) amorphous material in the composition. In certain embodiments, the percentage amorphous material is at least about 98% (w/w) or 99% (w/w). In various embodiments, the percent crystallinity of the composition ranges from about 0% (w/w) to about 10% (w/w), from about 20% (w/w) to about 70% (w/w), from about 30% (w/w) to about 60% (w/w) or from about 30% (w/w) to about 60% (w/w).

The stent may also be formed from blend of polymers, comprising a polymer formed from poly-L-lactide, poly-D-lactide or mixtures thereof and a copolymer moiety comprising poly-L-lactide or poly-D-lactide linked with ε-caprolactone or trimethylcarbonate. The poly- L-lactide or poly-D-lactide sequence in the copolymer moiety is random with respect to the distribution of ε-caprolactone or trimethylcarbonate and the wide-angle X-ray scattering (WAXS) exhibits 2Θ values of about 16.65 and about 18.96. The WAXS 2Θ values may further comprise peaks at about 12.00, about 14.80, about 20.67, about 22.35, about 23.92, about 24.92, about 29.16 and about 31.28.

Under DSC analysis, the polymer blend of the stent may exhibit T_m peaks at about 18O⁰C and about 217⁰C or about 178⁰C and about 22O⁰C.

BRIEF DESCRIPTION OF THE DRAWINGS

The Figures provided depict various embodiments that are described as illustrative examples that are not deemed in any way as limiting the present invention.

Figure 1 is a computer simulation illustration depicting a partial view of an embodiment of abioabsorbable medical device depicting a scaffold (stent) strut elements, nested hoop structures, end ring, locking mechanism and interconnection "H" regions.

Figure 2 is a computer generated illustration of an embodiment comprising a bioabsorbable stent design in an expanded configuration showing the nested hoop or ring structures, end ring, meandering strut element and locking mechanism.

Figure 3A depicts a computer simulation illustrating a prematurely expanded biabsorbable stent scaffold (stent) showing an alternating ring or hoop structures with a meandering strut element and locking mechanism. Figure 3B is the same stent scaffold (stent) as in Figure 3 A showing a ring segment in different states of stress.

Figure 4A illustrates is a planar view of an embodiment showing a bioabsorbable stent scaffold (stent) pattern which depicts a planar view of a bioabsorbable scaffold (stent) featuring repetitive strut pattern in the shape of an S which can be replaced with other designs as shown. Figure 4A also shows the nested hoop/rings structures. Figure 4B is an alternate embodiment in a planar configuration which illustrates the nested ring features, wherein the stent strut structure can be replaced with the design encompassed at 8. Figure 4C is a planar view illustration of an embodiment of the invention in which the structural pattern forms helical structures. Figure 4D illustrates a partial stent structure with hoop or ring structural elements and scaffold (stent)ing elements in the form as manufactured. Figure 4E illustrates the stent structure of Figure 4D in a partially expanded configuration. Figure 4F illustrates the stent structure of Figure 4D in an expanded configuration.

Figure 5 depicts an oblique view of a bioabsorbable stent embodiment exhibiting meandering strut segments in a sinusoidal pattern.

Figure 6A depicts a partial top view of expanded hoop or ring and meandering or sinusoidal (6B) bioabsorbable strut elements of a stent embodiment. Figure 6C illustrates a hoop or ring element of a bioabsorbable stent showing how radial/transverse load is distributed through a ring structure. As illustrated such structure provides a better distribution of forces keeping such stent open under forces that might otherwise cause deformation of the stent. Figure 6D illustrates a hoop undergoing progressive radial expansion. Figure 6E shows the stent ringlet undergoing increasing radial expansion. Figure 6F illustrates the phenomena referred to as "necking" as the cross section of the ringlet decreases in a specific section of the meandering element and crystallization spreads laterally around the ringlet.

Figures 7A-7C illustrates the polymer fibers alignment in embodiments of the bioabsorbable medical devices and how the alignment undergoes plastic deformation upon stress. Figure 7 A illustrates the amorphous state of the polymer composition for making the devices. Figure 7B illustrates the polymer fibers alignment in a partially expanded configuration and Figure 7C illustrates the crystalline state of the fibers upon expansion of a bioabsorbable stent embodiment.

Figure 8 A illustrates a planar view of a bioabsorbable stent scaffold (stent) embodiment comprising, structural meandering strut elements, nested hoop/ring elements and having end rings at the openings of the stent tube. Figure 8B is a planar view of a section of the stent scaffold (stent) of Figure 8 A illustrating the structural meandering strut elements, nested hoop/ring elements and connection strictures which form the stent scaffold (stent). The stent scaffold (stent) is shown in a state as manufactured and also shows the nested rings structures in various configurations and connections between structural meandering elements and hoop elements in the shape of a stylized letter H configuration. Figure 8C illustrates the segment of Figure 8B in an expanded configuration. Figure 8D, 8E and 8F are planar views of bioabsorbable stent scaffold (stent) walls showing alternate design embodiments of the connection elements which can be substituted between meandering strut elements. Figure 8G is a planar view of a bioabsorbable stent scaffold (stent) wall showing an alternate design embodiment of the strut and hoop/ring patterns and how the design can be modified by alternate connection elements to change the flexibility of the stent scaffold (stent). Figure 8H illustrates a stent scaffold (stent) as manufacture which shows the nested hoop/ring structure intercalated between meandering strut elements. Figure 81 is Figure 8H in a partially expanded configuration, and Figure 8J is the same as 8H in an expanded configuration and Figure 8K in a fully expanded configuration. Figure 9 A depicts a planar view illustration of a biabsorbable stent scaffold (stent) showing the various components, nested hoop/ring structural elements, meandering/sinusoidal strut components, end ring element and modified connection structures having an o-ring like shape where the elements meet. Figure 9B illustrates an oblique view of a stent structure scaffold (stent) as illustrated in Figure 9 A in an expanded configuration.

Figure 1OA illustrates the connection elements of a bioabsorbable scaffold (stent) as described in Figure 9A showing the state of the connections as manufacture; Figure 1OB and 1OC in a partially expanded state and Figure 1OD in a fully expanded state.

Figure 1 IA depicts a planar view of an unexpanded alternate bioabsorbable stent scaffold (stent) design showing alternate pattern of connections between strut elements and comprising end rings structures. Figure 1 IB is Figure 1 IA in an expanded configuration. Figure 11C illustrates a bioabsorbable stent structure as illustrated in Figure 1 IA mounted on a balloon catheter in an expanded configuration.

Figure 12A depicts a planar view of an alternate embodiment of a bioabsorbable stent scaffold (stent) structure showing alternate design for the strut elements in expanded configuration and hoop/ring elements. Figure 12B is a bioabsorbable stent structure of Figure 12A in an expanded configuration and mounted on a balloon catheter.

Figure 13A illustrates a bioabsorbable stent scaffold (stent) embodiment comprising radio-opaque marker structures positioned at the end ring and the connection elements between strut segments. Figure 13B illustrates an embodiment wherein the radio-opaque material is position in a diagonal pattern for identification by radiography of the device after implantation.

Figures 14A-14D illustrates alternate embodiments of isolated marker label structures of a bioabsorbable stent scaffold (stent) in cross-section.

Figures 15A and 15B further illustrate the position at which label radio-opaque markers are placed in a bioabsorbable stent scaffold (stent) embodiment and Figure 15C is a radiography of a radio-opaque marker label in a bioabsorbable stent strut embodiment.

Figure 16A is an illustration of a planar view of an end of a stent embodiment comprising an end ring element, a locking mechanism and a stent strut meandering element in an expanded configuration. Figure 16B is Figure 16A showing the stent scaffold (stent) in a crimped configuration. Figure 16C is an illustration of an the expanded stent scaffold (stent) showing the stress force distribution. Figure 16D illustrates a segment of a bioabsorbable stent scaffold (stent) embodiment showing nested hoop/ring structures, stent meandering segments and locking mechanisms or retention features which can alternate in design for engagement.

Figures 17A and 17B depict alternate embodiments of a stent scaffold (stent) in expanded planar view and showing disengage locking mechanisms and end ring structures at its ends.

Figures 18A-18F are illustrations of an alternate embodiment of a bioabsorbable stent scaffold (stent) showing the locking mechanism at the end rings of the device in planar and oblique views as well as disengage and engage positions. Figure 18G illustrates an embodiment wherein a stent scaffold (stent) is mounted on a balloon catheter and the locking mechanism are engage to retain the stent on the catheter in a uniform configuration in the plane of the body of the stent. Figure 18H is a frontal view of the stent scaffold (stent) of Figure 18G showing the catheter as a circle, end ring and balloon.

Figure 19A depicts a planar view of a stent scaffold (stent) embodiment showing an alternate embodiment of the locking mechanism at the ends of the stent as manufactured. Figure 19 B depicts Figure 19A in a crimped position showing an engaged locking mechanism. Figure 19C shows an enlarged planar view of the locking mechanism in the crimped position, partially expanded configuration (Figure 19D) and oblique views of the end rings with locking mechanism partially engaged (Figure 19E); crimped (Figure 19F) and mounted in a balloon catheter (Figure 19G). Figure 2OA depicts an planar view of an alternate design locking mechanism of bioabsorbable stent embodiment in an expanded configuration; crimped configuration (Figure 20B). Figure 2OC is a planar view of an end segment showing a snap-fit locked end in a crimped configuration and expanded (Figure 20D). Figure 2OE and 2OF represent oblique views of the stent scaffold (stent) of Figure 20A-20F in expanded and crimped configurations, respectively. Figure 2OG illustrates the stent scaffold (stent) mounted on a balloon catheter.

Figure 21 depicts a planar view of an end portion of a stent scaffold (stent) embodiment including an end ring element, a series of disengaged locking means and a stent strut meandering element in a relaxed state or partially expanded state.

Figure 22 further identifies functional and structural details of the locking means depicted in Figure 21. Figure 23 depicts a planar view of a gradual engagement sequence of a series of snap- fit locking steps A through E.

Figure 24 depicts an illustration of stent retention features wherein illustration (A) shows a disengaged locking means, illustration (B) shows an engaged locking means, and illustration (C) shows a crimped down, catheter mounted stent with a fully engaged (locked- in) locking means.

Figure 25 A and Figure 25B depicts an illustration of a radio-opaque particle contained in a base cavity 108 at a combined plug and receptacle portion of a locking device; Figure 25 C and Figure 25D depict illustrations of a CT scan visualization of such locking means containing radio-opaque particles cut from gold wire material.

Figure 26 depicts an illustration of a planar stent region with identification of the locking device details therein.

Figure 27 - DSC Pl 1228 Untreated (Raw) Material

Figure 28 - DSC Pl 1228 annealed at 12O⁰C for 15 minutes

Figure 29 - DSC Pl 1228 annealed at 12O⁰C for 15 minutes and stressed

Figure 30- DSC Pl 1369 Untreated

Figure 31- DSC Pl 1369 annealed at 8O⁰C for 15 minutes

Figure 32- DSC Pl 1369 annealed at 8O⁰C for 15 minutes and stressed

Figure 33- DSC Pl 1371 Untreated Figure 34- DSC P 11371 annealed at 8O⁰C for 15 minutes

Figure 35- DSC Pl 1371 annealed at 8O⁰C for 15 minutes and stressed

Figure 36- WAXS Pl 1228 Untreated

Figure 37a- WAXS Pl 1228 annealed at 12O⁰C for 15 minutes

Figure 37b- Peak Analysis WAXS Pl 1228 annealed at 12O⁰C for 15 minutes

Figure 38a- WAXS Pl 1228 annealed at 12O⁰C for 15 minutes and stressed

Figure 38b- Peak Analysis WAXS Pl 1228 annealed at 12O⁰C for 15 minutes and stressed

Figure 39- WAXS Pl 1369 Untreated

Figure 40a- WAXS Pl 1369 annealed at 8O⁰C for 15 minutes Figure 40b- Peak Analysis WAXS Pl 1369 annealed at 8O⁰C for 15 minutes

Figure 41a - WAXS Pl 1369 annealed at 8O⁰C for 15 minutes and stressed Figure 41b- Peak Analysis WAXS Pl 1369 annealed at 8O⁰C for 15 minutes and stressed

Figure 42- WAXS Pl 1371 Untreated

Figure 43a- WAXS Pl 1371 annealed at 8O⁰C for 15 minutes

Figure 43b- Peak Analysis WAXS Pl 1371 annealed at 8O⁰C for 15 minutes

Figure 44a- WAXS Pl 1371 annealed at 8O⁰C for 15 minutes and stressed

Figure 44b - Peak Analysis WAXS Pl 1371 annealed at 8O⁰C for 15 minutes and stressed

Figure 45a - Elongation Pl 1369 Figure 45b - Elongation P 11371

Figure 46a - Tensile Strength Pl 1369 Figure 46b - Tensile Strength Pl 1371

DETAILED DESCRIPTION OF THE INVENTION

The medical devices of the present invention comprise a plurality of meandering strut elements or structures forming a consistent pattern, such as ring-like structures along the circumference of the device in repeat patterns. The meandering strut structures can be positioned adjacent to one another and/or in oppositional direction allowing them to expand radially and uniformly throughout the length of the expandable scaffold (stent) along a longitudinal axis of the device. In one embodiment, the expandable scaffold (stent) can comprise specific patterns such as a lattice structure, dual-helix structures with uniform scaffold (stent)ing with optionally side branching.

Stent structures typically comprise a number of meandering patterns. By "meandering" it is meant moving along a nonlinear path. Because the physician needs to insert the stent in an unexpanded form into the vasculature, the meandering patterns are often sinusoidal in nature, i.e., have a repeating sequence of peaks and troughs. Often such sinusoidal structures are normalized such that each peak or trough is generally of the same distance as measured from a median line. By "non-sinusoidal" it is meant a pattern not having a repeating sequence of peaks and valleys, and not having a series of raised portions of generally the same distance as measured from a median line nor a series of depressed portions of generally the same distance as measured from a median line. A stent may be characterized as having three distinct configurations, an unexpanded state (as manufactured), a crimped state (a compressed state as compared to the unexpanded state), and an expanded state (as deployed as an implant in vivo).

In one embodiment, meandering struts may alternate with each other. Both primary meandering struts and secondary meandering or ringlet strut elements may be held in position with respect to each other in the crimped configuration as well as in the expanded or implanted configuration by means of special connectors of various shapes located at crossing points between adjacent struts. Each such crossing connector or a select number may be used in a repeat pattern. These connecting elements are capable of keeping the meandering struts of the scaffold (stent) embodiment in a regularly spaced position. These connectors are intended to withstand the change from the initial tube confirmation to a tightly crimped position on a delivery bulb/inserting device to a stretchedly expanded configuration. The stretching of such a stent scaffold (stent) stresses and crystallizes the component struts and hoops/rings into circularity concomitant with the overall cylindrical or cone-like shape.

The strut connecting elements or connectors may be arranged in repeat patterns to stabilize and connect adjacent meandering strut elements. This design is intended to keep the elastic flexible meandering struts located within the tube-like scaffold (stent) conformation.

In another embodiment, the invention comprises a cooling means or condition for immobilizing and stabilizing a plastic scaffold (stent) on the carrier system in a crimped and locked down configuration for increasing reliability of the delivery system. In yet another embodiment, the medical device comprises a polymeric scaffold (stent) structure which can orient and/or crystallize upon strain of deployment, for example during balloon dilation, in order to improve its mechanical properties. These mechanical properties include, but are not limited to, resistance to compression, recoiling, elastic.

The medical device comprises polymers having slow breakdown kinetics which avoid tissue overload or other inflammatory responses at the site of implantation. An exemplary medical device can be structurally configured to provide the ability to change and conform to the area of implantation and to allow for the normal reestablishment of local tissues. For example, the medical device can transition from a solid polymer state to a "rubbery state", allowing for easier surgical intervention, than, for example, with metal stents such as a stainless steel stent. The higher the deformed state, the higher strength that is imparted to the device structural component. Polymerization preferably proceeds by block polymerization of D and L isomeric forms of the polymers (discussed below) in order to achieve a polymeric racemate moiety that enhances the transition from generally amorphous configuration to an expansion-related stretch or strain induced crystalline realignment of the polymeric moiety. The mechanical properties concomitantly change from crimpable flexibility to hoop extended rigidity, most particularly the latter change occurring in the expansion of nested and end- positioned rings or hoops from secondary meandering struts. In one embodiment, pharmaceutical compositions can be incorporated with the polymers by, for example, admixing the composition with the polymers prior to extruding the device, or by grafting the compositions onto the polymer active sites, or coating the composition onto the device. The medical device can comprise any polymeric medical device for implantation including stents, grafts, stent grafts, synthetic vascular grafts, shunts, catheters, and the like. An exemplary medical device may be a stent, which is structurally configured with a first meandering/sinusoidal elements and having a number of nested second element that when expanded comprises ring-like structural elements.

The expanded implant may display mechanical properties such as a degree of rigidity and concomitant flexibility preventing dislocation or creep. Various embodiments of biodegradable polymeric stents, and/or stent walls with different configurations. For example, the stent is a tubular structure comprising a scaffold (stent) wherein the strut elements are designed to allow blood to traverse through open spaces between the elements. In particular the meandering struts are spaced so that most of the adjacent tissue surface remains available for contact with blood. The particular stent design features include different radial and longitudinal parameters depending on the size of the stent to be deployed. A stent configuration can be varied such as bifurcated or configured to allow for further deployment to other vessels distal to the site of initial implantation. A stent can contain a uniform and flexible scaffold (stent)ing modified with side-branches. After initial deployment of the stent in situ, a second stent can be inserted through the luminal walls of the first stent. In an embodiment, the medical device can be modified to include a radio-opaque, or radio lucent material for detecting its location after deployment or to ascertain the effects of long-term use (6 months or 2 years). There are different types of modifications available, such as e.g. diffuse or spot marking of the scaffold (stent). Accordingly the radio-opaque materials can be incorporated directly in the initial plastic composition either as an admixture or covalently bound component. Alternatively, the radio-opaque material can be placed in a plurality of specific spot receptacles regularly distributed on or in the scaffold (stent). Or the radio-opaque or radio lucent materials can by applied as part of a thin coating on the scaffold (stent). Therefore, the contrast detection enhancement of tissue implants by electron-dense or x-ray refractile markers is advantageous. Such markers can be found in biodegradable spot depots filled with radiopaque compositions prepared from materials known to refract x-radiation so as to become visible in photographic images. Suitable materials include without limit, 10-90% of radiopaque compounds or microparticles which can be embedded in biodegradable moieties, particularly in the form of paste like compositions deposited in a plurality of cup shaped receptacles located in preformed polymeric scaffold (stent) strut elements. The radiopaque compounds can be selected from x-radiation dense or refractile compounds such as metal particles or salts. Suitable marker metals may include iron, gold, colloidal silver, zinc, magnesium, either in pure form or as organic compounds. Other radiopaque material includes, tantalum, tungsten, platinum/iridium, or platinum. The radiopaque marker may be constituted with a binding agent of one or more aforementioned biodegradable polymer, such as PLLA, PDLA, PLGA, PEG, etc. To achieve proper blend of marker material a solvent system is includes two or more acetone, toluene, methylbenzene, DMSO, etc. In addition, the marker depot can be utilized for an anti-inflammatory drug selected from families such as PPAR agonists, steroids, mTOR inhibitors, Calcineurin inhibitors, etc. In one embodiment comprising a radioopaque marker, iron containing compounds or iron encapsulating particles are cross-linked with a PLA polymer matrix to produce a pasty substance which can be injected or otherwise deposited in the suitably hollow receptacle contained in the polymeric strut element. Such cup-like receptacles are dimensioned to within the width of a scaffold (stent) strut element. Heavy metal and heavy earth elements are useful in variety of compounds such as ferrous salts, organic iodine substances, bismuth or barium salts, etc. Further embodiments can utilize natural encapsulated iron particles such as ferritin that may be further cross-linked by cross-linking agents. Furthermore, ferritin gel can be constituted by cross-linking with low concentrations (0.1-2%) of glutaraldehyde. The radiopaque marker may be applied and held in association with the polymer in a number of manners. For example, the fluid or paste mixture of the marker may be filled in a syringe and slowly injected into a preformed cavity or cup-like depression in a biodegradable stent strut through as needle tip. The solvents contained in the fluid mixture can bond the marker material to the cavity walls. The stent containing radiopaque marker dots can be dried under heat/vacuo. After implantation, the biodegradable binding agent can breakdown to simple molecules which are absorbed/discharged by the body. Thus the radiopaque material will become dispersed in a region near where first implanted.

The scaffold (stent) mechanical properties may be time tested in situ for any retention of recoil and the presence of restenotic tissue. Similarly, scaffold (stent) polymer biodegradation and metabolism may be assessed by quantitative change measurement in echogenicity and tissue composition. Regional mechanical properties may be assessed by palpography (6 months; 2 years). Mass reduction over time of polymer degradation may be assessed by OCT (6 months; 2 years). Binary restenosis may be quantitatively measured with MSCT(18 m). The experimental evidence supports the advantages of the biodegradable and absorbable scaffold (stent) as used for example in a stent. It has been found that the scaffold (stent) performs like a metallic drug eluting stent (DES) in terms of acute delivery and conformity. However, it has been found that the emplaced scaffold (stent) is naturally absorbed and fully metabolized. Therefore, the bioabsorbable scaffold (stent), which may be in the form of a tube shaped stent, is metabolized completely leaving no permanent implant and leaves behind a healed natural vessel or tissue. The scaffold (stent) of this invention is compatible with CT imaging.

In one scaffold (stent) embodiment, the scaffold (stent) comprises a crimpable polymeric stent, which can be inserted by means of a balloon delivery system for vascular implantation. However, the flexible plasticity of the stent scaffold (stent) can lead to relaxation of the crimped configuration on the carrier system used for vascular insertion or delivery. Consequently, the crimped scaffold (stent) may acquire the tendency to "creep" that is move-off the intended location of the balloon carrier or come loose entirely. Therefore, in one embodiment, the polymeric device such as a stent is provided with a safety mechanism for guarding against accidental opening of the scaffold (stent) while being mounted or loaded onto a delivery system and during deployment of the crimped device to a desired location within the tubular organ. The securing mechanisms can be designed adjacent to the circumferential distal and proximal end ring struts (secondary meandering strut elements). In specific embodiments, the scaffold (stent) has now been furnished with locking means to keep the crimped structure in a securely clamped position to prevent buckling and for secure deployment of the device. In addition, the locking means can prevent a loosening of the crimped configuration of the plastic scaffold (stent) from the carrier system during handling. The locking mechanism is affected by structurally interfering design and/or by added factional properties which may be activated by mutual pressure engagement. According to an embodiment, frictional aspects of the locking mechanism may be affected by selectively modified plastic compositions, where ionic or non-ionic additive substances may contribute to secure the crimped configuration of a scaffold (stent).

In specific embodiments, the scaffold (stent) employs various designs including snap- fit features at or near the distal and proximal end to lock the scaffold (stent) in the crimped position on the carrier portion of the delivery system. In this and other embodiments, one or more snap-fit structures can be designed, positioned at the end meandering strut element of a scaffold (stent) structure or alternatively also in certain repeat positions within scaffold (stent) structure. As intended in the crimped configuration, the locking mechanism increases stent retention force. Adjacent snap-fit locking features are designed to be continuous or attached to or part of a secondary meandering or ring/hoop structure, and are operatively configured to engage and lock-down the ends of the scaffold (stent) device in the crimped position to afford a sufficient retentive force for holding the scaffold (stent) in place along the longitudinal axis of the device and maintain uniformity of its diameter. In certain embodiments, and upon expansion of the device, the end meandering element may form a completely straightened ring for added hoop strength of, for example, a stent.

As described above, the device may be provided with a structural locking means in the form of key-in-lock configuration members, where the design resembles a snap-fit ball-socket joint type interlocking means. In one embodiment, there is provided one or more nested elemental meandering structures for forming loops or ring-like patterns in an expanded configuration.

The invention also includes processes for making the medical devices. A suitable polymer composition is prepared with or without one or more pharmaceutical substances. The polymer is then molded or extruded to configure the device for implantation. In the case of a stent, a tube shaped structure is formed and it is subsequently cut with, for example, the aid of a laser to form desired patterns. In one embodiment, a method for fabricating the medical device comprises preparing a biodegradable polymeric structure; designing said polymeric structure to be configured to allow for implantation into a patient; laser cutting said structure into patterns configured to permit traversing of the device through openings and to allow for crimping of the device. The patterned structure may contain the locking means for stabilizing the crimped device so as to retain it securely on the carrier/implant system. In another embodiment, closure means of locking devices for aiding in crimping and loading a scaffold (stent) configuration may be further chemically modified or enhanced by adding biocompatible non- ionic or ionic agents to the scaffold (stent) or scaffold (stent) composition or in the form of layers or grafts. These modified anionic, cationic or nonionic layers can be uniform or minutely stippled onto the interlocking surfaces. The dosage levels of the cationic or anionic agents which may also be surfactants may range from about 0.01 to about 10% by weight. External application of such ionic agents is preferred for easy soluble removal after expansion in situ. Low dosage levels of non- ionic agents are suitable for enhancing factional interaction particularly between parts of locking mechanism. Preferred are nonionic agents which may be FDA approved at dosage levels ranging from 0.05-2.5%. An embodiment for the friction-enhanced scaffold (stent), or particularly, the interacting lock surfaces, provides non-ionic doping of the modified layers. Suitable nonionic agents may be selected from chemicals such as ethoxylated fatty amines, fatty acid esters, and mono- and diglycerides.

The bioabsorbable polymers and compositions of the present invention may be formed into balloon-expandable stents that can be crimped onto a balloon delivery catheter system for delivery into a blood vessel. Alternatively, the bioabsorbable stents may be self-expanding. The balloon expandable medical device comprises a thermal balloon or a non-thermal balloon. The properties of the bioabsorbable polymers allow for both crimping and expansion of the stent on the balloon catheter without crazing. The crystal properties of the bioabsorbable polymers may change during crimping and/or expansion allowing for improved mechanical properties such as tensile strength, creep and slower degradation kinetics.

During breakdown, the bioabsorbable polymers of the present invention exhibit lower immunogenicity, e.g., decreased IL-2 or other cytokine production, as compared with other bioabsorbable polymers that are seen in the prior art. The in vitro degradation kinetics of the present bioabsorbable polymers show less about 5% overall breakdown after storage for 1 month at physiological conditions (e.g., phosphate buffered saline at 37⁰C); in other embodiments, the overall breakdown is less than about 10%, 20%, 30% or 40% after storage for 1 month, 2 months, 3 months or 6 months at physiological conditions. As defined herein, overall breakdown encompasses change in molecular properties, e.g., crystalline properties, mass loss or loss of mechanical properties. When formed into a stent, the bioabsorbable polymers of the present invention retain sufficient mechanical strength to maintain patency of a blood vessel for at least about 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 1 year, 2 years or 3 years after implantation. The stents of the present invention can be configured to conform to any vessel shape.

Figure 1 is a computer simulation depicting a partial view of an embodiment of a bioabsorbable medical device in unexpanded form. Reference 10 is the scaffold or stent. Meandering strut elements 17 are depicted together with nested hoop structures 14 and end rings 16, both comprising structures not in the same plane, locking mechanism 18 connected to another locking mechanism (not shown) and interconnection "H" regions 15 that may have an ring expansion through-hole 11 at the nested hoop structures 14.

Figure 2 is a computer generated illustration of an embodiment comprising a bioabsorbable stent design in a nearly expanded configuration showing the nested hoop structures 14 (or ring structures) and end rings 16 now in generally in the same plane, meandering strut element 17 and locking mechanism 18 detached from another locking mechanism. Expansion through-hole 11 as shown has been stretched into an oblong hole in such expanded configuration. Figure 3 A depicts a computer simulation illustrating a prematurely expanded biabsorbable stent scaffold (stent) showing an alternating ring or hoop structures with a meandering strut element 17 and locking mechanism 18. Figure 3B is the same stent scaffold (stent) as in Figure 3 A showing a ring segment in a different state of stress. In either case, the structure comprising each ring or hoop is generally in the same plane.

Figure 4 A illustrates a planar view of an embodiment showing a stent scaffold (stent) pattern 13, which may be bioabsorbable, in the shape of an S (19) which can be replaced with other designs as shown at 6. Figure 4 A also shows the nested hoop/rings structures 14. Figure 4B is an alternate embodiment in a planar configuration which illustrates the nested ring features 14, wherein the stent strut structure can be replaced with any of the design encompassed at 8. Figure 4C is a planar view illustration of an unexpanded scaffold (stent) embodiment of the invention in which the structural sinusoidal strut element 17 forms helical patterned structures 9 in the overall structure (shown as diagonal patterns in the planar view). Figure 4D illustrates a partial unexpanded stent structure formed of the scaffold (stent) of Figure 4C with hoop or ring structural elements 14 and scaffold (stent) elements in the form as manufactured. Figure 4E illustrates the stent structure of Figure 4D in a partially expanded configuration. Figure 4F illustrates the stent structure of Figure 4D in an expanded configuration with each ring as a cylindrical shape in substantially the same plane.

Figure 5 depicts an oblique view of an unexpanded bioabsorbable stent embodiment exhibiting meandering strut segments 22 in a sinusoidal pattern and end ring 23. Figure 6 A depicts a partial top view of an expanded hoop or ring, while Figure 6B illustrates such hoop or ring when not expanded, shown in the drawing as composed of meandering sinusoidal (6B) bioabsorbable strut elements of a stent embodiment. Figure 6C illustrates a hoop or ring element of a bioabsorbable stent showing how radial/transverse load is distributed through a ring structure. As illustrated such structure provides a better distribution of forces keeping such stent open under forces that might otherwise cause deformation of the stent. Figure 6D illustrates a hoop undergoing progressive radial expansion. Figure 6E shows the stent ringlet undergoing increasing radial expansion. The meandering element straightens and then undergoes deformation. The modulus of stretching could range from about 250,000 PSI to about 550,000 PSI. Deformation includes a decrease in the cross sectional dimension of one segment of the meandering element (the width and thickness). One meandering element (segment) of the ringlet may undergo deformation with subsequent change in crystallization and/or decrease in the cross sectional area showing a specific wide-angle X-ray scattering (WAXS) 2Θ values ranging from about 1 to about 35 after stretching, e.g., about 1, 2, 3, 4 ,5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 28, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34 or 35. In one embodiment, the cross sectional area decreases without any accompanying change in the crystal structure. During radial expansion, the number of segments of the meandering elements undergoing such crystal formation and decrease in cross sectional area increases from 1, 2, 3 to n until the entire meandering element or stent ringlet (hoop) has undergone such transformation. This phenomena, which can also be referred to as "necking" as the cross section of the ringlet decreases in a specific section of the meandering element and crystallization spreads laterally around the ringlet. Figure 6F. "The necking phenomena in polymers is well known and usually occurs when a homogeneous solid polymeric bar (film or filament), with a non- monotonous dependence of axial force S on stretching ratio λ, is stretched uniaxially ... In this case the polymer bar is not deformed homogeneously. Instead, two almost uniform sections occur in the sample: one being nearly equal to its initial thickness and another being considerably thinner in the cross-sectional dimensions." See, for example, Leonov, A.I., A Theory of Necking in Semi-Crystalline Polymers, Int'l J. of Solids and structures, 39 (2002)5913-5916; see also, http://www.eng.uc.edu/~gbeaucag/ Classes/Characterization/StressStrainhtml/ StressStrain.html (May 6, 2010); see also, http://materials.npl.co.uk/NewIOP/ Polymer.html (May 6, 2010). In addition to WAXS, birefringence or differential scanning calorimetry may be measured on the samples. Stretching may also be assessed by subjecting the samples to mechanical drawing using a universal Instron Testing Machine. Wong et al. Acta Materialia: 56: 5083-5090 (2008). Drawing may be conducted at the drawing temperature Td which may be the same or different from the glass transition temperature T_g of the polymers. For example, drawing temperatures may range from about 65⁰C to about 12O⁰C.

Figures 7A-7C illustrates the polymer fibers alignment in embodiments of the bioabsorbable medical devices and how the alignment undergoes plastic deformation upon stress. Figure 7 A illustrates the amorphous state of the polymer composition for making the devices. Figure 7B illustrates the polymer fibers alignment in a partially expanded configuration and Figure 7C illustrates the crystalline state of the fibers upon expansion of a bioabsorbable stent embodiment composed of racemate or stereocomplex polymeric compositions.

Figure 8 A illustrates a planar view of an unexpanded bioabsorbable stent scaffold (stent) embodiment comprising, structural meandering strut elements 17, nested hoop/ring elements 14 and having end rings 16 at the openings of the stent tube. Figure 8B is a planar view of a section of the stent scaffold (stent) of Figure 8 A illustrating the structural meandering strut elements 17, nested hoop/ring elements 28, 30 and connection structures which form the stent scaffold (stent). The stent scaffold (stent) is shown in a state as manufactured and also shows the nested rings structures 28, 30 in various configurations.

Focusing on the connections between structural meandering elements and hoop elements there may be seen the shape of a stylized letter H. Figure 8C illustrates the segment of Figure 8B in an expanded configuration. Figure 8D, 8E and 8F are planar views of bioabsorbable stent scaffold (stent) walls showing alternate design embodiments A - G of the connection points between meandering strut elements 17. A' - G' in FIG. 8E are planar views corresponding to patterns A - G in FIG. 8D. In FIG. 8F, a stent scaffold pattern 13 in the shape of an S (19) can be replaced with other designs as shown at 2. FIG. 8F also shows the nested hoop/rings structures 14. Figure 8G is a planar view of a bioabsorbable stent scaffold (stent) wall showing an alternate design embodiments of the strut and hoop/ring patterns and how the design can be modified by alternate connection elements 3 to change the flexibility of the stent scaffold (stent). Figure 8H illustrates a stent scaffold (stent) as manufacture which shows the nested hoop/ring structure intercalated between meandering strut elements. Figure 81 is Figure 8H in a partially expanded configuration, and Figure 8J is the same as 8H in an expanded configuration and Figure 8K in a fully expanded configuration.

Figure 9 A depicts a planar view illustration of a biabsorbable stent scaffold (stent) showing the various components, nested hoop/ring structural elements 28, meandering/sinusoidal strut components 38, end ring elements 16 and modified connection structures 9 having an o-ring like shape where the elements meet. Figure 9B illustrates an oblique view of a stent structure scaffold (stent) as illustrated in Figure 9 A in an expanded configuration. Figure 1OA illustrates the connection structures of a bioabsorbable scaffold (stent) as described in Figure 9A showing the state of the connections as manufactured; Figure 1OB and 1OC in a partially expanded state and Figure 1OD in a fully expanded state. As illustrated the through- void shape changes as the scaffold (stent) is expanded.

Figure 1 IA depicts a planar view of an unexpanded alternate bioabsorbable stent scaffold (stent) design showing alternate pattern of connections 55 between strut elements. Figure 1 IB is Figure 1 IA in an expanded configuration. Figure 11C shows the same in expanded state deployed on a expanded balloon catheter.

Figure 12A depicts a planar view of an alternate embodiment of a bioabsorbable stent scaffold (stent) structure showing alternate design for the strut elements in expanded configuration including hoop/ring elements 14 and 16. Figure 12B may be a bioabsorbable stent structure of Figure 12A in an expanded configuration and mounted on a balloon catheter.

Figure 13A illustrates another bioabsorbable stent scaffold (stent) embodiment (see also, U.S. Patent Nos. 7,682,384 and 7,329,277, and U.S. Patent Publication Nos. 20090024207, 20090024198, 20080319537, 20080294244, 20080294243, 20080294241, 20080288053, 20080288052, 20080288051, 20080288050, 20080281407 and U.S. Patent Application Serial No. 12/727,567 for further description of this embodiments) comprising radio-opaque marker structures 65 positioned at the end ring and the connection elements between strut segments. Figure 13B illustrates an embodiment wherein the radio-opaque material is position in a diagonal pattern 65' for identification by radiography of the device after implantation. Figure 14A-14D illustrates alternate embodiments of isolated marker label structures of a bioabsorbable stent scaffold (stent) in cross-section. As illustrated the isolated marker may be placed on the stent (14D), or in a recess (14B) or in a variety of through-holes (14A and 14C).

Figures 15A and 15B further illustrate the position at which label radio-opaque markers 65 are placed in a bioabsorbable stent scaffold (stent) embodiment. Figure 15C is a close-radiograph of a radio-opaque marker label in a bioabsorbable stent strut embodiment.

A variety of different locking mechanisms to hold the stent on the catheter may be employed. In one scaffold (stent) embodiment, the scaffold (stent) comprises a crimpable polymeric stent, which can be inserted by means of an expandable balloon delivery system for vascular implantation. However, the flexible plasticity of the stent scaffold (stent) can lead to relaxation of the crimped configuration on the carrier system used for vascular insertion or delivery. This plasticity is particularly enhanced by the body temperature of the treated patient. Consequently, the crimped scaffold (stent) acquires the tendency to "creep" that move off the intended location of the balloon carrier or come loose entirely. Therefore, in preferred embodiments, the polymeric device such as a stent is provided with a safety mechanism for guarding against accidental opening of the scaffold (stent) while being mounted or loaded onto a delivery system and during deployment of the crimped device to a desired location within the tubular organ. Multiple safety mechanism are disclosed herein which can be used with a medical device. Exemplary embodiments of securing or safety mechanism designs which can be effective in securing the plastic scaffold (stent) onto a delivery system are disclosed in Figures 16-26.

The locking efficacy of the snap-fit polymer scaffold (stent) is enhanced by strain crystallization induced during the arrowhead insertion portion captured by the hook elements of the receptor portion. However, during the expansion phase of the scaffold (stent) during deposit the polymer constitution allows smearing or deformation of the struts or locking means as these stress points of the locks yield to the radial expansion force. The particularly advantageous behavior of the locking elements is achieved by the special strain-crystallizing characteristic of the polymer composition used for the scaffold or stent. The securing mechanisms can be designed adjacent to the circumferential distal and proximal end ring struts (secondary meandering strut elements), as well as anywhere within the stent pattern so as to limit creep or what is known as plastic structural relaxation of the crimped down stent embodiment. The so-called creep may result in movement or rearrangement of the crimped stent on the balloon carrier. In specific embodiments, the scaffold (stent) has therefore been furnished with locking means to keep the crimped structure in a securely clamped position to prevent buckling and for secure deployment of the device. In addition, the locking means can limit or prevent a loosening of the crimped configuration of the plastic scaffold (stent) from the carrier system during handling. This handling may entail the procedure for inserting and guiding the stent through the challenging tortuosity of the arterial vascular system. Most particularly, the locked down crimped stent entity has to withstand the hazardous travel through diseased vasculature of a patient. The diseased arteries exhibiting thrombus encased plaques may show thorn-like calcified outcroppings or spurs that are liable to piercingly deflate the balloon carrier or hook into the balloon carrier or catheter-attached stent. Therefore the strength of the number of locks of whatever design may range from one, two, three to as many locks as can be fitted around a crimped circumference. Part of the possible number of locks resides in the size of the very locks in use. The locks are preferentially installed in an equidistant manner about the circumference of a stent so that for example, two locks are distributed about 180 degrees from each other, three locks about 120 degrees from each other, or four locks about 60 degrees from each other. The locking mechanism is affected by structurally interfering design and/or by added frictional properties which may be activated by mutual pressure engagement. According to an embodiment, frictional aspects of the locking mechanism may be affected by selectively modified plastic compositions, wherein ionic or non- ionic additive substances may contribute to secure the crimped configuration of a scaffold (stent).

In specific embodiments, the scaffold (stent) employs various designs including snap- fit features at or near the distal and proximal end to lock the scaffold (stent) in the crimped position on the carrier portion of the delivery system. In this and other embodiments, one or more snap-fit structures can be designed, positioned at the end meandering strut element of a scaffold (stent) structure or alternatively also in certain repeat positions within scaffold (stent) structure. As intended in the crimped configuration, the locking mechanism increases stent retention force. Adjacent snap-fit locking features are designed to be continuous or attached to or part of a secondary meandering or ring/hoop structure, and are operatively configured to engage and lock-down the ends of the scaffold (stent) device in the crimped position to afford a sufficient retentive force for holding the scaffold (stent) in place along the longitudinal axis of the device and maintain uniformity of its diameter. In certain embodiments, and upon expansion of the device, the end meandering element may form a completely straightened ring for added hoop strength of, for example, a stent.

As described above, the device is provided with a structural locking means in the form of key-in-lock configuration members, wherein the design resembles a snap-fit ball-socket joint type interlocking means, in one embodiment, there is provided one or more nested elemental meandering structures for forming loops or ring-like patterns in an expanded configuration.

The scaffold (stent) embodiment may be configured in number of ways. For example, one may use end ring type locking positions in the form of a snap-fit where a cantilever shape or finger strut element fits tightly over an adjacent counterpressuring strut surface when locked down in the crimped configuration of the stent. Locking means comprise in another embodiment, a finger-like cantilever extension that engagingly slides in a snap-fit manner over a commensurately curved surface portion of the adjacent piece of the plastic scaffold (stent) strut element. In this embodiment, the securing mechanism works as a break or friction device which creates sufficient friction to keep the scaffold (stent) end in the crimped-down position. An alternative locking means is illustrated in locked form of a ball joint snap-fit locking means.

Another embodiment of the snap-fit locking means is illustrated in Figure 19 or 20 in locked and unlocked configuration, wherein the cantilever embodiment utilizes a notch style receptacle form on an adjacent strut element to receive the tip portion of the cantilever.

In one embodiment, the structural locking means of the medical device can be designed in key-in-lock or ball-joint configuration wherein the oppositely oriented cantilever hook-type interlocking means in a locked and unlocked position.

Figure 16A is an illustration of a planar view of an end of a stent embodiment comprising an end ring element 16, a locking mechanism 75 and a stent strut meandering element 17 in an expanded configuration. Figure 16B is Figure 16A showing the stent scaffold (stent) in a crimped configuration with interlocking locking mechanisms 75. Figure 16C is an illustration of an expanded stent scaffold (stent) showing the stress force distribution, and showing the decoupling of locking mechanisms 75 when in the stent is in an expanded configuration. Figure 16D illustrates a segment of a bioabsorbable stent scaffold (stent) embodiment showing nested hoop/ring structures 14, stent meandering strut elements 17 and locking mechanisms 75 or retention features which can alternate in design for engagement.

Figure 17A and 17B depict alternate embodiments of a stent scaffold (stent) in expanded planar view and showing disengage locking mechanisms 75 and end ring structures 16 at its ends. FIGS. 17A and 17B also depict connection elements 42 between strut elements. As shown mechanisms 75 are snap-fit connections with male-female portions. Figure 18A-18F are illustrations of an alternate embodiment of a bioabsorbable stent scaffold (stent) showing the locking mechanism 75 at the end rings of the device in planar and oblique views as well as disengage and engage positions. Locking mechanism 75 in such embodiment comprises a snap-fit ball joint. Figure 18A, 18D and 18E show disconnected locking mechanism 75. Figure 18B, 18C and 18F show the locking mechanism 75 in locked state. Figure 18G illustrates an embodiment wherein the a stent scaffold (stent) is mounted on a balloon catheter 60 and the locking mechanism are engaged to retain the stent on the catheter in a uniform configuration in the plane of the body of the stent. Figure 18H is a frontal view of the stent scaffold (stent) 16 of Figure 18G showing the catheter as a circle 60, end ring 16 and balloon 70. Figure 19A depicts a planar view of a stent scaffold (stent) embodiment showing an alternate embodiment of the locking mechanism 80 at the ends of the stent as manufactured. Figure 19 B depicts Figure 19A in a crimped position showing an engaged locking mechanism. Figure 19C shows an enlarged planar view of the locking mechanism in the crimped position, partially expanded configuration (Figure 19D) and oblique views of the end rings with locking mechanism partially engaged (Figure 19E); crimped (Figure 19F) and mounted on a balloon catheter (Figure 19G).

Figure 2OA depicts an planar view of an alternate design locking mechanism 90 of bioabsorbable stent embodiment in an expanded configuration; crimped configuration (Figure 20B). Figure 2OC is a planar view of an end segment showing a snap-fit locked end in a crimped configuration and expanded (Figure 20D). Figure 2OE and 2OF represent oblique views of the stent scaffold (stent) of Figure 20A-20F in expanded and crimped configurations, respectively. Figure 2OG illustrates the stent scaffold (stent) mounted on a balloon catheter.

Figure 21 depicts a planar view of an end portion of a stent scaffold (stent) embodiment 120 including an end ring element 121, a series of disengaged locking means and a stent strut meandering element 122 in a relaxed state or partially expanded state. The locking device 99 is uniquely combining both receptor 107 and insertion 100 components as well as a cavity or pocket 106 for storing radio-opaque matter.

Figure 22 further depicts an alternate embodiment of a locking mechanism for a tube- shaped device. Figure 22 shows functional and structural details of the locking means 99 depicted in Figure 21. Thus, the particular shape of the insertion component 100 can be inserted into oppositely located receptor portion 107 so that the arrow- like head-shaped insertion tip 101 abuts with a stopper element 105 causing a compression thereof. The abutting of arrowhead 101 with the stopper 105 inside the receptor portion 107 can further cause a deformation of the stopper 105 region so as to form receptor hook elements 102 lining both sides of the receptor portion 107. Receptor hook elements 102 have projections which deflect inward at the stopper adjacent pivot points 104. Consequently, the hook elements 102 engage the interference surfaces 103 so as to lock- in the arrow head 100 within the receptor portion 107. The mutual contact pressure between the hook elements 102 and the arrowhead 101 retention surfaces 103 produces a strain on the polymeric material such that the contacting surfaces crystallize and thereby harden so as to stabilize the locking function/effect of the closed locking device, see Figure 23.

Figure 23 depicts a planar view of the embodiment of Figure 22, showing a gradual engagement sequence of a series of snap-fit locking steps A through E. Step A depicts the position of the insertion portion 100 oriented to engage the proximal receptor portion 107; step B illustrates the initial contact between the inclined surfaces of the arrowhead tip 101 and the oppositely oriented surfaces of both hook elements 102 of the receptor 107; step C further illustrates the displacement and plastic deformation of the hook elements 102 at the respective pivot points 104; step D depicts an initial insertion contact of the arrowhead 101 at the point of collision with the stopper 105, where the displaced hook elements 102 have not yet returned to their original receptor positions 107 (step A); and step E illustrates the locking position wherein the hook elements 102 have returned to their original receptor positions 107; and thus engagingly contact the arrowhead interference surfaces 103. The position of the hook elements are stable due to the strain crystallization of the pivot region caused by the collision force of locking the insert portion into the receptor portion that is achieved through the crimping operation.

Figure 24 depicts a tripartite illustration montage of the embodiment of Figure 22 showing a stent retention structure wherein illustration (A) shows a disengaged locking means 160 located in a relaxed stent pattern; illustration (B) shows an engaged locking means in a crimped down stent, and illustration (C) shows a catheter mounted stent 200 which is crimped down on balloon type catheter, and secured with a fully engaged (locked- in) locking means 99.

Figure 25 A and Figure 25B depicts an illustration of the embodiment of Figure 22, showing a radio-opaque particle 108 that was incorporated into the stent structure of Figure 25 A, such as for example, a gold kernel encased in a cavity 108 of the locking means 160 between a plug portion and a receptacle portion of the snap-fit lock. Figure 25C and Figure 25D depict illustrations of a CT scan visualization of such closed locking means 160 containing radio-opaque gold particles such that the vascular location of the stent may be ascertained in situ.

Figure 26 depicts a planar pattern of the stent embodiment of Figure 22, containing portions of unlocked locking devices 250, wherein each pocket 108 specifically may encompass radio-opaque matter. The other details of the locking device are indicated as in

Figure 21. Furthermore, the secure containment of the gold particles in the designated pockets of locked locking devices is shown in the photograph of Figure 25. This aspect answers the practicality of this of type marker arrangement which helps the visualization of the implant. Polymer implant embodiments may be nearly undetectable due to lack of mass density or absence of signal. Therefore, such embodiments may incorporate a radio opaque marker, such a radio opaque dots as illustrated in Figure 1 -Figure 9 and Figure 24-Figure 26 Such dots may be produced by applying radiopaque material in paste form into rivet-like depressions or receptacles in or on the scaffold (stent) strut elements, or cut from radio-opaque material such as gold wire. As shown, regular patterns of radiopaque dot deposits on the scaffold (stent) or more particularly in pockets or cavities of locking devices would advantageously aid in the ease of radiological detection of such implant location. Bioabsorbable polymers represent a wide range of different polymers. Typically, bioabsorbable polymers comprise aliphatic polyesters based on lactide backbone such as poly L-lactide, poly D-lactide, poly D,L-lactide, meso lactide, glycolides, lactones, as homopolymers or copolymers, as well as formed in copolymer moieties with co-monomers such as, trimethylene carbonate (TMC) or ε-caprolactone (ECL). U.S. Patent No. 6,706,854; U.S. Patent No. 6,607,548; EP 0401844; and Jeon et al. Synthesis and Characterization of Poly (L-lactide) - Poly (ε-caprolactone). Multiblock Copolymers Macro molecules 2003: 36, 5585 - 5592. The copolymers comprises a moiety such as L-lactide or D-lactide of sufficient length that the copolymer can crystallize and not be sterically hindered by the presence of glycolide, polyethylene glycol (PEG), ε-caprolactone, trimethylene carbonate or monomethoxy-terminated PEG (PEG-MME). For example, in certain embodiments greater than, 7, 8, 9, 10, 50, 75, 100, 150 or 250 L or D-lactides may be arrayed sequentially in a polymer. Fukushima et al. Sterocomplexed polylactides (Neo-PLA) as high-performance bio- based polymers: their formation, properties and application. Polymer International 55:626-642 (2006). These blocks of L or D-lactides may allow for cross moiety crystallization even with the addition of an impact modifier to the blend composition. Such a blend makes it possible to design device specific polymer compositions or blends by producing either single or double Tg's (glass transition temperatures). Cross moiety crystallization of compositions with copolymers typically occurs with those blends with copolymers with co-monomer molar ratios ranging from about 50:50 to about 60:40, 99:1, 95:5, 90:10, 88:12, 70:30 or 80:20.

The bioabsorbable polymers of the present invention comprise a wide range of polymer mixtures at different concentrations. For example, the amounts of lactide polymers such as poly L-lactide, poly D-lactide or poly D,L-lactide or blend of any of the foregoing, can range from about 20% (w/w) to about 95% (w/w). Percent weights may also range from about 50% (w/w) to about 95% (w/w), from about 60% (w/w) to about 95% (w/w), from about 70% (w/w) to about 95% (w/w) or from about 70% (w/w) to about 80% (w/w) of the polymers. In one embodiment, a composition can comprise about 70% (w/w) poly L-lactide having an inherent viscosity (IV) of about 2.0 to about 4.4 or about 2.5 to about 3.8, mixed with the copolymer moiety such as poly L-lactide-co-trimethylene carbonate (TMC) (70/30 mole/mole) having an IV of about 1.2 to about 1.8 or about 1.4 to about 1.6. In another embodiment, the polymer formulation comprises a blend having about 70% (w/w) of the triblock poly L-lactide-co-polyethylene glycol (PEG) (99/01 mole/mole) having an IV ranging from about 2.0 to about 4.8, about 1.2 to about 4.8 or about 2.5 to about 3.8 which is mixed with the poly L-lactide-co-TMC (70/30 mole/mole) having an IV of about 1.2 to about 1.8 or about 1.4 to about 1.6. In yet another embodiment, the polymer composition comprises a blend having about 70% (w/w) of a diblock poly L-lactide-co-PEG-MME (95/05 mole/mole) having an IV ranging from about 2.0 to about 4.4, or about 2.5 to about 3.8, mixed with poly L-lactide-co-TMC (70/30 mole/mole) having an IV ranging from about 1.2 to about 1.8 or about 1.4 to about 1.6.

The polymer composition may also comprise a blend having about 70% (w/w) of a diblock, poly L-lactide-co-PEG-MME (monomethyl ethers) (95/5 mole/mole) having an IV ranging from about 2.0 to about 4.4, or about 2.5 to about 3.8, mixed with poly L-lactide-co- TMC (about 60/40 mole/mole to about 80/20 mole/mole, with about 70/30 mole/mole being one embodiment) having an IV ranging from about 1.2 to about 1.8 or about 1.4 to about 1.6. If ε-capro lactone is substituted for TMC in the co-polymer, the IV of the co-polymer ranges from 1.2 to 2.6 (note, this applies to any substitution of TMC with any ε-capro lactone).

In yet another embodiment, the polymer composition comprises a blend having about 20% - 45% (w/w) poly-L-lactide, about 35% (w/w) to about 50% (w/w) poly-D-lactide and about 10% (w/w) to about 35% (w/w) poly L-lactide-co-TMC (about 60/40 to about 80/20 mole/mole, with about 70/30 mole/mole being one embodiment) or poly-L-lactide- ε- caprolactone.

Another embodiment may contain about 33% (w/w), 47% (w/w) and about 20% (w/w) or about 40% (w/w), 40% (w/w) and about 20% (w/w) of the respective components: poly-L- lactide, poly-D-lactide, poly L-lactide-co-TMC (about 60/40 to about 80/20 mole/mole, with about 70/30 mole/mole being one embodiment) or poly-L-lactide- ε-caprolactone, respectively.

The co-polymer of the blend which comprises poly-L-lactide-co-TMC or poly-L- lactide- ε-caprolactone can have an IVs ranging from about 0.8 - 2.6, 1.2 - 2.6, 1.2 - 1.8 or 1.4 - 1.6 (if TMC is substituted for ε-caprolactone, then the IV of the co-polymer may range from about 0.8 to 6.0, 1.2 - 2.4, 1.4 - 1.6, 2.0 - 2.4). The polymer bends may also comprise copolymer mixtures of poly-L-lactide- ε- caprolactone and poly L-lactide-co-TMC in varying ratios from 10:1 (w/w) to 1 :10 (w/w). The polymer composition and blends of the present invention may allow for the formation of a lactide racemate or stereo-complex crystal structure between the L and D moieties; in certain embodiments, the stero-complex crystal structure may form between an active pharmaceutical ingredient, small molecule, peptide or protein or an excipient. These types of crystals further enhance the mechanical properties of the stent or medical device. The formation of the racemate (stereo complex) crystal structure can result from formulations comprising combinations of: poly L-lactide with poly D-lactide and poly L-lactide-co-TMC; poly D-lactide with poly L-lactide-co-TMC; poly L-lactide with poly D-lactide-co-TMC; poly L-lactide with poly D-lactide with poly D-lactide-co-TMC; poly L-lactide-co-PEG with poly D-lactide-co-TMC; and, poly D-lactide-co-PEG with poly L-lactide-co-TMC, di-block poly D-co-L-lactide with poly L(or D)-lactide-co-TMC and di-block poly D-co-L-lactide with poly L(or D)-lactide-co-TMC (in each case shown above, ε-caprolactone may be substituted for TMC).

When crystallized from the melt or from solution, homogeneous solutions of poly-L- lactide or poly-D-lactide adopt left- or right-handed IO3 helix conformations, respectively, and produce the R crystal form by arranging by pair in a crystalline unit cell. The ^? crystal form, which is only found in solution- spun fibers drawn at high temperatures, features six 3i helices in an orthorhombic unit cell and can rearrange to the more stable R crystal form. When crystallized from the melt or from solution, blends of poly-L-lactide and poly-D-lactide can form a racemic sterocomplex. The melting point of this complex (230⁰C) is 50⁰C higher than that of the R crystal form of the pure polyenantiomers. Brochu et al. Sterocomplexation and Morphology of Polylactides. Macromolecules:5230-5239 (1995). Polymers blends may also form an amorphous mixture. U.S. Patent No. 6,794,485. The percentage crystallinity may be determined by Differential Scanning Calorimetry (DSC). Sarasua, et al. Crystallinity and mechanical properties of optically pure polylactides and their blends. Polymer Engineering and Science: 745-753 (2005).

Poly-lactide racemate compositions also offer the ability to be "cold formable or bendable" without adding heat which can be important if the polymer blend incorporates a pharmaceutical agent which is susceptible to denaturation. Cold-bendable scaffold (stent)s of the invention do not require heating to become flexible enough to be crimped onto a carrier device or to accommodate irregularly shaped organ spaces. Cold- formable, includes physiological and ambient temperatures ranging from about 15⁰C to about 37.5⁰C. When implanted in an organ space such as pulsating vascular lumen, cold-bendable scaffold (stent)s can afford sufficient flexibility for an expanded scaffold (stent) device. For example, in terms of a stent, in certain embodiments, it is desirable to utilize polymeric compositions that possess significant amount of amorphous polymer moieties after fabrication and crystallize when the scaffold (stent) is strained by crimping onto a delivery balloon or by stretching upon balloon expansion for implantation. Such cold-bendable polymeric scaffold (stent) embodiments do not need to be preheated to a flexible state prior to implantation onto a contoured surface space in the body. Cold-bendability also allows these polymer blends to be both crimped and expanded at physiological and ambient temperature without crazing.

Martins et al. Control the Strain-Induced Crystallization of Polyethylene Terephthalate by Temporally Varying Deformation Rates: A Mechano-optical Study. Polymer. 2007: 48, 2109- 2123.

Other examples of bioabsorbable polymers that may be used with the methods of the present invention include, aliphatic polyesters, bio glass cellulose, chitin collagen copolymers of glycolide, copolymers of lactide, elastin, tropoelastin, fibrin, glycolide/1-lactide copolymers (PGA/PLLA), glycolide/trimethylene carbonate copolymers (PGA/TMC), hydrogel lactide/tetramethylglycolide copolymers, lactide/trimethylene carbonate copolymers, lactide/- ε-caprolactone copolymers, lactide-σ-valerolactone copolymers, L- lactide/dl- lactide copolymers, methyl methacrylate-N-vinyl pyrrolidone copolymers, modified proteins, nylon- 2 PHBA/γ-hydroxyvalerate copolymers (PHBA/HVA), PL A/poly ethylene oxide copolymers, PLA-polyethylene oxide (PELA), poly (amino acids), poly (trimethylene carbonates), poly hydroxyalkanoate polymers (PHA), poly(alklyene oxalates), poly(butylene diglycolate), poly(hydroxy butyrate) (PHB), poly(n-vinyl pyrrolidone), poly(ortho esters), polyalkyl-2- cyanoacrylates, polyanhydrides, polycyanoacrylates, polydepsipeptides, polydihydropyrans, poly-dl- lactide (PDLLA), polyesteramides, polyesters of oxalic acid, polyglycolide (PGA), polyiminocarbonates, polylactides (PLA), polyorthoesters, poly-p-dioxanone (PDO), polypeptides, polyphosphazenes, polysaccharides, polyurethanes (PU), polyvinyl alcohol (PVA), poly-β-hydroxypropionate (PHPA), poly-β-hydroxybutyrate (PBA), poly-σ- valero lactone, poly-β-alkanoic acids, poly-β-malic acid (PMLA), poly-ε-caprolactone (PCL), pseudo-Poly(Amino Acids), starch, trimethylene carbonate (TMC) and tyrosine based polymers. U.S. Patent No. 7,378,144.

Pharmaceutical compositions may be blended into the polymers or may be coated on the polymer blends by spraying, dipping or painting. U.S. Publication Nos. 2006/0172983 Al, 2006/0173065 Al, 2006/188547 Al, 2007/129787 Al. Alternatively, the pharmaceutical compositions may be microencapsulated and then blended into the polymers. U.S. Patent No. 6,020,385. If the pharmaceutical compositions are covalently bound to the polymer blend, they may be linked by hetero- or homo-bifunctional cross linking agents to the monomer or polymer (see, htt|κ//wΛvw^^ It is understood that the polymer blends having pharmaceutical compositions blended, coated or attached may be prepared without undue experimentation.

The pharmaceutical compositions can include (i) pharmacological agents such as, (a) anti-thrombotic agents such as heparin, heparin derivatives, urokinase, and PPack (dextrophenylalanine proline arginine chloromethylketone); (b) anti-inflammatory agents such as dexamethasone, prednisolone, corticosterone, budesonide, estrogen, sulfasalazine and mesalamine; (c) antineoplastic/antiproliferative/anti-miotic agents such as paclitaxel, 5- fluorouracil, cisplatin, vinblastine, vincristine, epothilones, endostatin, angiostatin, angiopeptin, monoclonal antibodies capable of blocking smooth muscle cell proliferation, thymidine kinase inhibitors, rapamycin, 40-0-(2- Hydroxyethyl)rapamycin (everolimus), 40- 0-Benzyl -rapamycin, 40-0(4'-Hydroxymethyl)benzyl-rapamycin, 40-0- [4'-(I ,2-

Dihydroxyethyl) Jbenzyl-rapamycin, 40-Allyl-rapamycin, 40-0-[3'-(2,2- Dimethyl- 1,3- dioxolan-4(S)- yl-prop-2'-en- l'-yl]- 20 rapamycin, (2':E,4'S)-40-0-( 4',5'.:Dihydroxypent-2'- en-l '-yl),r apamycin 40-0(2 Hydroxy) ethoxycar-bonylmethyl-rapamycin, 40-0-(3- Hydroxypropyl-rapamycin 40-0-( (Hydro xy)hexyl-rapamycin 40-0- [2-(2- Hydroxy)ethoxy]ethyl-rapamycin, 40-0-[(3S)-2,2Dimethyldioxolan-3-yl]methyl-rapamycin, 40-0-[ (2S)-2,3- Dihydroxyprop-l-yl]-rapamycin, 40-0-(2- Acctoxy)ethyl-rapamycin, 40-0-(2- Nicotinoyloxy)ethyl-rapamycin, 40-0-[2-(N-25 Morpholino) acetoxyethyl-rapamycin, 40-0- (2-N-Imidazolylacetoxy)ethyl-rapamycin, 40-0 [ 2-(N-Methyl- N'-piperazinyl)acetoxy]ethyl- rapamycin, 39-0-Desmethyl-3.9,40-0,0 ethylene- rapamycin, (26R)-26- Dihydro-40-0-(2-hydroxy)ethyl-rapamycin, 28-0 Methyrapamycin, 40- 0-(2-Aminoethyl)-rapamycin, 40-0-(2-Acetaminoethyl)-rapamycin 40-0(2- Nicotinamidoethyl)-rapamycin, 40-0-(2-(N-Methyl- imidazo- 2' ylcarbcthoxamido)ethyl)- 30 rapamycin, 40-0-(2-Ethoxycarbonylaminoethyl)-rapamycin, 40-0-(2-Tolylsulfonamidoethyl)- rapamycin, 40-0-[2-(4',5'-Dicarboethoxy-r,2';3'-triazol-l '-yl)-ethyl]rapamycin, 42-Epi- (telrazolyl)rapamycin (tacrolimus), and 42-[3-hydroxy-2-(hydrox ymethyl)-2- methylpropanoate Jrapamycin (temsirolimus) (WO2008/086369); (d) anesthetic agents such as lidocaine, bupivacaine and ropivacaine; (e) anti-coagulants such as D-Phe-Pro-Arg chloromethyl ketone, an RGD peptide-containing compound, heparin, hirudin, antithrombin compounds, platelet receptor antagonists, anti-thrombin antibodies, anti-platelet receptor antibodies, aspirin, prostaglandin inhibitors, platelet inhibitors and tick antiplatelet peptides; (f) vascular cell growth promoters such as growth factors, transcriptional activators, and translational promoters; (g) vascular cell growth inhibitors such as growth factor inhibitors, growth factor receptor antagonists, transcriptional repressors, translational repressors, replication inhibitors, inhibitory antibodies, antibodies directed against growth factors, bifunctional molecules consisting of a growth factor and a cytotoxin, bifunctional molecules consisting of an antibody and a cytotoxin; (h) protein kinase and tyrosine kinase inhibitors (e. g. , tyrphostins, genistein, quinoxalines); (i) prostacyclin analogs; (j) cholesterol-lowering agents; (k) angiopoietins; (1) antimicrobial agents such as triclosan, cephalosporins, aminoglycosides and nitrofurantoin; (m) cytotoxic agents, cytostatic agents and cell proliferation affectors; (n) vasodilating agents; and, (o) agents that interfere with endogenous vasoactive mechanisms, (ii) genetic therapeutic agents include anti-sense DNA and RNA as well as DNA coding for (a) anti-sense RNA, (b) tRNA or rRNA to replace defective or deficient endogenous molecules, (c) angiogenic factors including growth factors such as acidic and basic fibroblast growth factors, vascular endothelial growth factor, epidermal growth factor, transforming growth factor a and P, platelet-derived endothelial growth factor, platelet-derived growth factor, tumor necrosis factor a, hepatocyte growth factor and insulin- like growth factor, (d) cell cycle inhibitors including CD inhibitors, and (e) thymidine kinase ("TK") and other agents useful for interfering with cell proliferation.

Other pharmaceutical agents that may be incorporated into the polymer blends, include, acarbose, antigens, beta-receptor blockers, non-steroidal antiinflammatory drugs (NSAID;, cardiac glycosides, acetylsalicylic acid, virustatics, aclarubicin, acyclovir, cisplatin, actinomycin, alpha- and beta-sympatomimetics, (dmeprazole, allopurinol, alprostadil, prostaglandins, amantadine, ambroxol, amlodipine, methotrexate, S-amino salicylic acid, amitriptyline, amoxicillin, anastrozole, atenolol, azathioprine, balsalazide, beclomcthasone, betahistine, bezafibrate, bicalutamide, diazepam and diazepam derivatives, budesonide, bufexamac, buprcnorphine, methadone, calcium salts, potassium salts, magnesium salts, candesartan, carbamazepine, captopril, cefalosporins, cetirizine, chenodeoxycholic acid, ursodeoxycholic acid, theophylline and theophylline derivatives, trypsins, cimetidine, clarithromycin, clavulanic acid, clindamycin, clobutinol, clonidinc, cotrimoxazole, codeine, caffeine, vitamin D and derivatives of vitamin D, colestyramine, cromoglicic acid, coumarin and coumarin derivatives, cysteine, cytarabine, cyclophosphamide, cyclosporin, cyproterone, cytabarine, dapiprazole, desogestrel, desonide, dihydralazine, diltiazem, ergot alkaloids, dimenhydrinate, dimethyl sulphoxide, dimeticone, domperidone and domperidan derivatives, dopamine, doxazosin, doxorubizin, doxylamine, dapiprazole, benzodiazepines, diclofenac, glycoside antibiotics, desipramine, econazole, ACE inhibitors, enalapril, ephedrine, epinephrine, epoetin and epoetin derivatives, morphinans, calcium antagonists, irinotecan, modafmil, orlistat, peptide antibiotics, phenytoin, riluzoles, risedronate, sildenafil, topiramatc, macro lide antibiotics, oestrogen and oestrogen derivatives, progestogen and progestogen derivatives, testosterone and testosterone derivatives, androgen and androgen derivatives, ethenzamide, etofenamate, ctofibrate, fcnofϊbrate, etofyne, etoposide, famciclovir, famotidine, felodipine, fenoftbrate, fentanyl, fenticonazole, gyrase inhibitors, fluconazole, fludarabine, fluarizine, fluorouracil, fluoxetine, flurbiprofen, ibuprofen, flutamide, fluvastatin, follitropin, formoterol, fosfomicin, furosemide, fusidic acid, gallopamil, ganciclovir, gemfibrozil, gentamicin, ginkgo, Saint John's wort, glibenclamide, urea derivatives as oral antidiabetics, glucagon, glucosamine and glucosamine derivatives, glutathione, glycerol and glycerol derivatives, hypothalamus hormones, goserelin, gyrase inhibitors, guanethidine, halofantrine, haloperidol, heparin and heparin derivatives, hyaluronic acid, hydralazine, hydrochlorothiazide and hydrochlorothiazide derivatives, salicylates, hydroxyzine, idarubicin, ifosfamide, imipramine, indometacin, indoramine, insulin, interferons, iodine and iodine derivatives, isoconazole, isoprenaline, glucitol and glucitol derivatives, itraconazole, ketoconazole, ketoprofen, ketotifen, lacidipine, lansoprazole, levodopa, levo methadone, thyroid hormones, lipoic acid and lipoic acid derivatives, lisinopril, lisuride, lofepramine, lomustine, loperamide, loratadine, maprotiline, mebendazole, mebeverine, meclozine, mefenamic acid, mefloquine, meloxicam, mcpindolol, meprobamate, meropenem, mesalazinc, mesuximide, metamizole, metformin, methotrexate, methylphenidate, methylprednisolone, metixene, metoclopramide, metoprolol, metronidazole, mianserin, miconazole, minocycline, minoxidil, misoprostol, mitomycin, mizolastinc, moexipril, morphine and morphine derivatives, evening primrose, nalbuphine, naloxone, tilidine, naproxen, narcotine, natamycin, neostigmine, nicergoline, nicethamide, nifedipine, niflumic acid, nimodipine, nimorazole, nimustine, nisoldipine, adrenaline and adrenaline derivatives, norfloxacin, novamine sulfone, noscapine, nystatin, ofloxacin, olanzapine, olsalazine, omeprazole, omoconazole, ondansetron, oxaceprol, oxacillin, oxiconazole, oxymetazoline, pantoprazole, paracetamol, paroxetine, penciclovir, oral penicillins, pentazocine, pentifylline, pentoxifylline, perphenazine, pethidine, plant extracts, phenazone, pheniramine, barbituric acid derivatives, phenylbutazone, phenytoin, pimozide, pindolol, piperazine, piracetam, pirenzepine, piribedil, piroxicam, pramipexole, pravastatin, prazosin, procaine, promazine, propiverine, propranolol, propyphenazone, prostaglandins, protionamide, proxyphylline, quetiapine, quinapril, quinaprilat, ramipril, ranitidine, reproterol, reserpine, ribavirin, rifampicin, risperidone, ritonavir, ropinirole, roxatidine, roxithromycin, ruscogenin, rutoside and rutoside derivatives, sabadilla, salbutamol, salmeterol, scopolamine, selegiline, sertaconazole, sertindole, sertralion, silicates, sildenafil, simvastatin, sitosterol, sotalol, spaglumic acid, sparfloxacin, spectinomycin, spiramycin, spirapril, spironolactone, stavudine, streptomycin, sucralfate, sufentanil, sulbactam, sulphonamides, sulfasalazine, sulpiride, sultamicillin, sultiam, sumatriptan, suxamethonium chloride, tacrine, tacrolimus, taliolol, tamoxifen, taurolidine, tazarotene, temazepam, teniposide, tenoxicam, terazosin, terbinafme, terbutaline, terfenadine, terlipressin, tertatolol, tctracyclins, teryzoline, theobromine, theophylline, butizine, thiamazole, phenothiazines, thiotepa, tiagabine, tiapride, propionic acid derivatives, ticlopidine, timolol, tinidazole, tioconazole, tioguanine, tioxolone, tiropramide, tizanidine, tolazolinc, tolbutamide, tolcapone, tolnaftate, tolperisone, topotecan, torasemide, antioestrogens, tramadol, tramazoline, trandolapril, tranylcypromine, trapidil, trazodone, triamcinolone and triamcinolone derivatives, triamterene, trifluperidol, trifluridine, trimethoprim, trimipramine, tripelennamine, triprolidine, trifosfamide, tromantadine, trometamol, tropalpin, troxerutine, tulobutcrol, tyramine, tyrothricin, urapidil, ursodeoxycholic acid, chenodeoxycholic acid, valaciclovir, valproic acid, vancomycin, vecuronium chloride, Viagra, venlafaxine, verapamil, vidarabine, vigabatrin, viloazine, vinblastine, vincamine, vincristine, vindesine, vinorclbinc, vinpocetine, viquidil, warfarin, xantinol nicotinate, xipamide, zafirlukast, zalcitabine, zidovudine, zolmitriptan, Zolpidem, zoplicone, zotipine and the like. See, e.g., U.S. Patent No. 6,897,205; see also, U.S. Patent No. 6,838,528; U.S. Patent No. 6,497,729.

The medical device can comprise any medical device for implantation including stents, coverings for electrodes, catheters, leads, implantable pacemaker, cardioverter or defibrillator housings, dural closures or sutures, spine cages, joints, screws, rods, ophthalmic implants, femoral pins, hip replacements, bone plates, grafts such as bone graft containment devices, graft fixation, anastomotic devices, perivascular wraps, sutures, staples, shunts for hydrocephalus, dialysis grafts, colostomy bag attachment devices, drainage tubes, leads for pace makers and implantable cardioverters and defibrillators, vertebral disks, bone pins, suture anchors, hemostatic barriers, clamps, screws, plates, clips, vascular implants, tissue adhesives and sealants, tissue scaffold (stent)s, various types of dressings (e.g., wound dressings), bone substitutes, intraluminal devices, vascular supports, etc.

In one embodiment, the medical device comprises a stent that is structurally configured to expand in situ when deployed into an artery or a vein and to conform to the blood vessel lumen to reestablish blood flow at the site of injury. The stent can be configured to have many different arrangements so that it is crimpable before deployment and expandable at physiological conditions once deployed. The medical device of present invention includes various embodiments of biodegradable polymeric stents, and/or stent walls with different configuration. U.S. Patent Nos. 6,117,165, 7,108,714 and 7,329,277 represent several examples of such stents. The stent may be a tubular structure comprising struts designed to allow blood to traverse its walls so that the adjacent tissues are bathed or come in contact with it as blood flows through the area. The particular stent design depends on the size of the stent both radially and longitudinally.

The present invention also provides for methods of making a bioabsorbable polymeric implant comprising: blending a crystallizable polymer composition which comprises a base polymer of poly L-lactide and/or poly D-lactide linked with modifying copolymers comprising poly L (or D)-lactide-co-TMC or poly L(or D)-lactide-co-ε-caprolactone in the form of block copolymers or as blocky random copolymers where the lactide chain length is sufficiently long enough to allow cross-moiety crystallization together with poly-L-lactide or poly-D-lactide polymers at various concentrations; molding, extruding or casting the polymer composition to structurally configure an implant such as a stent; and cutting the implant to form desired patterns. In various embodiments greater than, 7, 8, 9, 10, 50, 75, 100, 150 or 250 L or D-lactides may be arrayed sequentially in a polymer. Fukushima et al. Sterocomplexed polylactides (Neo-PLA) as high-performance bio-based polymers: their formation, properties and application. Polymer International 55:626-642 (2006).

Polymerization reactions are well known to one skilled in the synthesis of polymers. Its principles, applications, and techniques such as initiation and molecular weight control for the polymerization reactions, can be found in George Odian, Principles of Polymerization, 4^th Ed ©2004 Wiley-Interscience. The polymers, poly -L-lactide and poly-D-lactide may be prepared by polymerization of the corresponding monomers. The most commonly used catalyst is stannous octoate, but other catalysts such as dibutyl tin(IV) and tin(II) chloride can also be employed. The polymerization reactions can also be initiated with an initiator, for example, ethylene glycol or a long chain alcohol. The reaction can be carried out as fusion polymerization, bulk polymerization, or any other polymerization technology known to a person of skill in the art. The synthesis of the polymers is disclosed in U.S. Patent Nos. 6,706,854, 6,607,548, EP 0401844WO 2003/057756 and WO 2006/111578 . Jeon et al. Synthesis and Characterization of Poly (L-lactide) - Poly (ε-capro lactone) Multiblock Copolymers. Macromolecules 2003: 36, 5585 - 5592. The synthesis of Poly-L-lactide-co-ε- caprolactone is also disclosed in Macromolecules 2003: 36, 5585-5592. In addition, the polymers are available commercially. Vendors include, http : //www.purac. com, http://www.bochringcr-ingclheim.co m/corporatα^/home/homc.asp, ww w. lakcshorebio . com and http://www.absorbables.com''. The range of IV for the polymers includes about 1.2 to about 4.4, about 1.2 to about 1.8, about 2.0 to about 4.4 and about 2.5 to about 3.8. In certain embodiments, polymers with IV less than about 2.0 and greater than about 4.5 may be used. For example, poly-L-lactide of the desired molecular weight is synthesized from the lactide monomer by ring-opening polymerization. L-lactide (1 mol), stannous octoate [5 mmol, monomer/catalyst ratio (M/C)) 200] and 1,6-hexanediol (25 mmol) are weighed into a round-bottomed flask equipped with a mechanical stirrer. The product is dissolved in chloroform and microfiltered through a 0.45 μm pore membrane filter. The polymer is precipitated by pouring the polymer solution into an excess of methanol, filtered, and dried under vacuum. It is a known technique in the art that reaction conditions, such as M/C, reaction temperature and reaction time, can be modified to control the molecular weight of the poly-L-lactide. Though the preferred catalyst is stannous octoate, other catalysts such as tin(II) chloride or initiator such as ethylene glycol can also be employed. The Tm of the poly- L-lactide polymer typically ranges from about 16O⁰C to about 194⁰C and the IV from about 2.0 to about 4.4 (see, for example, U.S. Patent Nos. 6,706,854, 6,607,548, EP 0401844WO 2003/057756 and WO 2006/111578).

Poly-D-lactide of desired molecular weight may be synthesized from the lactide monomer by ring-opening polymerization. D-lactide (1 mol), stannous octoate [5 mmol, monomer/catalyst ratio (M/C)) 200], and 1,6-hexanediol (25 mmol) are weighed into a round- bottom flask equipped with a mechanical stirrer. The flask is purged with dry nitrogen and immersed in an oil bath at 130⁰C for 5 h. The product is dissolved in chloroform and micro filtered through a 0.45 μm pore membrane filter. The polymer is precipitated by pouring the polymer solution into an excess of methanol, filtered, and dried under vacuum. It is a known technique in the art that reaction conditions, such as M/C, reaction temperature and reaction time, can be modified to control the molecular weight of the poly-D-lactide. The preferred catalyst is stannous octoate, but other catalysts such as tin(II) chloride or initiator such as ethylene glycol can also be employed. The T_m of the poly-D-lactide polymer typically ranges from about 16O⁰C to about 194⁰C and the IV from about 2.0 to about 4.4.

Random Copolymers moieties are synthesized from the D- or L-lactide and ε- caprolactone monomers by ring-opening polymerization. U.S. Patent Nos. 6,197,320, 6,462,169, 6,794,485. Caprolactone (100 mmol), D- or L-lactide (100 mmol), stannous octoate (1 mmol), and 1,6-hexanediol (0.5 mmol) are weighed into a glass ampule equipped with a magnetic stirring bar. The ampule is sealed under vacuum after purging three times with nitrogen at 90⁰C and heated to 150⁰C in an oil bath for 24 h with stirring. After reaction, the ampule is broken; the polymer is then dissolved in chloroform and micro filtered through a 0.45 μm pore membrane filter. It is precipitated by pouring the polymer solution into an excess of methanol, filtered, and dried under vacuum. By controlling the reaction conditions, such as lactide/ε-caprolactone ratio, monomer/catalyst ration, reaction temperature and reaction time, the molecular weight of the copolymer moiety is controlled. The preferred catalyst is stannous octoate; however, other catalysts such as tin(II) chloride or initiator or ethylene glycol can be employed. By controlling the molar ratios of the D- or L-lactides, the number of L-lactides arrayed in sequence in the random copolymer moiety can be controlled, which may range from 10 - 20, 20 - 30, 30 - 40, 40 - 50, 100 - 150 or from 150 - 200. (see, for example, EP 1468035 Bl, U.S. Patent No. 6,706,854, WO 2006/111578 Al and WO 03057756 Al). TMC may be substituted for ε-caprolactone in the above synthesis procedures.

In various embodiments, di-block copolymers containing poly-L-Lactide and poly-D- Lactide may be used. The use of a di-block copolymer of L- and D-lactide during polymer mixture blending can enhance the formation of the racemate crystal structure having both D- and L- lactides over homo-enantiomer co-crystallization.

During synthesis of the lactide polymers, monomers may be extracted from the reaction by either driving the reactions to "completion" and/or use of known extraction techniques such as solvent extraction or supercritical CO₂ extraction. U.S. Patent No. 5,670,614.

Polymers used for controlled drug delivery must be biocompatible and degrade uniformly into non-toxic molecules that are non-mutagenic, non-cytotoxic and noninflammatory. Examples of polyanhydrides and polyesters that are useful in the preparation of the present polymer blends include polymers and copolymers of lactic acid, glycolic acid, hydroxybutyric acid, mandelic acid, caprolactone, sebacic acid, l,3-bis(p- carboxyphenoxy)propane (CPP), bis-(p-carboxyphenoxy)methane, dodecandioic acid (DD), isophthalic acid (ISO), terephthalic acid, adipic acid, fumaric acid, azeleic acid, pimelic acid, suberic acid (octanedioic acid), itaconic acid, biphenyl-4,4'-dicarboxylic acid and benzophenone-4,4'-dicarboxylic acid. Polymers may be aromatic, aliphatic, hydrophilic or hydrophobic.

The polymer blends are formed using known methods such as solvent mixing or melt mixing. In the solvent mixing procedure, the desired weight of each of the polymers to be blended is mixed in the desired amount of an appropriate organic solvent or mixture of solvents and the polymer solutions mixed. The organic solvent is then removed, for example, by evaporation, leaving a polymer blend residue. Pharmaceutically active agents or additives may be incorporated into the polymer blends by dissolving or dispersing the pharmaceutically active agent or additive in the blend solution prior to removal of the solvent. This method is especially useful for the preparation of polymer blends incorporating pharmaceutically active agents that are sensitive to elevated temperatures.

In the melt mixing procedure, the polymers are melted together or brought separately to each polymer's respective melting temperature and then mixed with each other for a defined time period, e.g., from about two to about thirty minutes (5, 10, 15, 20 and 25 minutes). The blend is then allowed to cool to room temperature. Pharmaceutically active agents or additives may be incorporated by dissolving or dispersing them either in the blend solution or in the individual melt solutions prior to blending. U.S. Patent Publication No. 2006/0172983.

The glass transition temperature (Tg), crystallization temperature (T_c) and melting temperature (T_m) are critical characteristics of the polymer blend. The miscibility of the blended polymers is indicated by a single glass transition temperature (T_g) of the blend (either shifted or broadened from the constituents of the blend). A blend with two or more T_g indicates degrees of immiscibility of the polymers. The polymer blend may also present no melting temperature (T_m) indicating an amorphous polymer blend or single or multiple melting temperatures. Multiple melting temperatures indicate crystalline polymer where the crystals are either single or multiple homo-enantiomer, or co-moiety crystals such as the stereocomplex or racemate crystal structure between poly-L and poly-D-lactides. The present invention comprises a polymorphic polymer system having varying degrees of miscibility (and thus domain size) which affects both mechanical properties and degradation kinetics.

The molecular weight or viscosity of the polymer blend is typically an average of the molecular weights and viscosities of the component polymers. The polymers can be blended together using melt kneading such as a two-roll mill, a Banbury mixer, a single-screw, twin- screw extruder, intermeshing co-rotating screw extruders and multiscrew extruders. Chris Rauwendaal. Mixing in Polymer Processing. Wiley, 1993; http://www.rauwcndaal.com/⁷; wwvLrajidcasilCiCom. The polymer blend may also be processed by sheet extrusion, profile extrusion, blown film extrusion, blow molding, rotational molding, thermoform processing, compression molding, transfer molding or injection molding. www.me.Qatech.edu/iOnathan.colton/me4210/polymer.pdf. In one embodiment, poly-L-lactide, poly-D-lactide and poly-L-lactide-co-TMC (or ε- caprolactone) are dry-blended together. Raw material components are dry-blended in a multi- axial Turbula type blender under dry N₂ after each component has been dried. The dry-blend is then fed into an extruder or injection molding machine. Alternatively, the dried components may be individually metered into the extruder or molding machine. After extrusion, the polymer blend is processed at temperatures ranging from their T_g (glass transition temperature) to above the T_m of the racemate.

During mixing in the extruder or molding machine, the polymer components soften and/or melt, then flow in the extruder or molding machine plasticating unit. They may be visualized as independent melt domains until action of the plasticating screw(s) causes intimate mixing by application of both shear and extensional flows. This forced intimacy between the lactide enantiomers allows for formation of a racemate crystal structure. Because of the high Molecular weights, racemate gels can form in this melt at temperatures above the T_m of the enantiomers, i.e., 18O⁰C but below the T_m of the racemate 23O⁰C. Racemate crystallization begins at about 195⁰C, necessitating higher melt temperatures possibly exceeding the Tm of the racemate and/or additional mixing and melt extension. The T_m of the poly-L-lactide/poly-D-lactide racemate of the present invention typically ranges from about 195⁰C to about 235⁰C. Brochu et al. Sterocomplexation and Morphology of Polylactides. Macromolecules 1995 28:5230. The polymer blend may also be melt cast or transferred to a compression mold

(transfer mold). The polymer may be molded or extruded to form a finished device. Alternatively, the polymer blend could be solution or gel cast. In solution or gel casting, during removal of the solvent phase, crystallization occurs in the polymer blend. By controlling the solvent removal rate, inter-moiety crystallization may be controlled. The solvent cast films or tubes can undergo further isothermal recrystallization thermal treatment. In melt processes, by introducing a high degree of mixing in the melt and by enhancing this temperature above the T_m of the enantiomers, stereocomplex formation of high Mw Polylactides crystals is enhanced. Brochu et al. Sterocomplexation and Morphology of Polylactides. Macromolecules 1995 28:5230. Finished or semi- finished devices or components may undergo further isothermal recrystallization thermal treatment. The polymer compositions may be prepared from commercially available granular materials and copolymer additives. In one embodiment, the dry components are weighed according to the desired weight ratio into a container rotating for 30 minutes or until a homogenous mixture is obtained, and may be followed by further drying, for example, in a vacuum at 6O⁰C for 8-12 hours or overnight. The thoroughly mixed components may be melt blended and injection molded into a pair of matching plates. The composition may be extruded at a melt temperature 185 -25O⁰C using a screw with a length to diameter ratio ranging from 16 to 32/1 or 24 - 26/1 at 2-100 rpm. The polymer blends may be extruded to form, for example, tubes, sheets or fibers. The tubes may be cut into stents or sheets. Additionally, the sheets of fibers may be cut and fabricated into stents.

Stents form scaffold (stent)s that may be used in angioplasty. The stents are positioned in narrowed vessel lumens to support the vessel walls. Placement of a stent in the affected arterial segment prevents elastic recoil and closing of the artery. Stents also prevent local dissection of the artery along the medial layer of the artery. Stents may be used inside the lumen of any physiological space or potential space, such as an artery, vein, bile duct, urinary tract, alimentary tract, tracheobronchial tree, cerebral aqueduct or genitourinary system. Stents may also be placed inside the lumen of human as well as non- human animals. In general there are two types of stents: self-expanding and balloon-expandable. The balloon- expandable stent is placed in a diseased segment of a vessel by inserting a crimped stent into the affected area within the vessel. The stent is expanded by positioning a balloon inside the stent. The balloon is then inflated to expand the stent. Inflation remodels the arterial plaque and secures the stent within the affected vessel.

In contrast, a self-expanding stent is capable of expanding by itself. There are many different designs of self-expanding stents, including, coil (spiral), circular, cylinder, roll, stepped pipe, high-order coil, cage or mesh. U.S. Patent No. 6,013,854. The self-expanding stent is placed in the vessel by inserting the stent in a constrained state into the affected region, e.g., an area of stenosis. Once the constraining sheath is withdrawn, the stent freely expands to a preset diameter. The stent may be compressed using a tube that has a smaller outside diameter than the inner diameter of the affected vessel region. When the stent is released from confinement in the tube, the stent expands to resume its original shape and becomes securely fixed inside the vessel against the vessel wall. The stent is formed from a hollow tube made of bioabsorbable polymer. Notches or holes are made in the tube forming the elements of the stent. The notches and holes can be formed in the tube by use of a laser, e.g., UV Eximer lasers" or "Femtosecond lasers". High- repetition-rate low-pulse-energy near-infrared femtosecond laser pulses from a Ti:sapphire oscillator may be used to micromachine localized refractive index structures inside polymers. The formation of the notches and holes to prepare the claimed stent is considered within the knowledge of a person of ordinary skill in the art. The polymer blends may also be injection molded to a finished or semi-finished shape. Yoklavich et al. Vessel Healing Response to Bioaborbable Implant. Fifth World Biomaterials Congress. May 29 - June 2, 1996, Toronto, Canada.

To facilitate placement of the stent within the patient, electron-dense or x-ray refractile markers may be mixed with the polymeric material prior to blending. Radiopaque compounds can be selected from x-radiation dense or refractile compounds such as metal particles or salts. Suitable marker metals may include iron, gold, colloidal silver, zinc, magnesium, either in pure form or as organic compounds, tantalum, tungsten, platinum/iridium, platinum or radioopaque ceramics such as zirconium oxide. To achieve proper blend of marker material a solvent system may include two or more acetone, toluene, methylbenzene, DMSO.

The physical parameters of the polymer mixture can be characterized using a variety of different methods. The following list is nonexhaustive and other methodologies may also be utilized. The molecular weight and distribution of the polymers can be measured by gel permeation chromatography (GPC) or size exclusion chromatography (SEC) (e.g., Waters HPLC systems 410 differential refractometer, three PLGeI columns (HR2, HR4, and HR5E), 515 pump). Average molecular weight (Mw), the number average molecular weight (Mn) and molecular weight distribution may be determined by GPC. "Molecular weight distribution" refers to Mw divided by Mn. One could also use dilute solution viscometry to measure intrinsic viscosity which can be correlated to molecular weight of the polymers (see, for example, www .boehrin ger-inge lheim.com/.. ,/ic/ .../N02-06_I V_vs_SEC .pdf, October 10, 2009). Differential scanning calorimetry (DSC) may be used to study the thermal properties, degree of crystallinity and stereocomplexation of the present compositions. In one embodiment, the result of a DSC measurement using a Differential Scanning Calorimeter is a curve of heat flux versus temperature. Examples of the properties of the polymer that may be obtained using DSC include glass transition temperatures (Tg), crystallization temperature (T_c) and melting temperature (T_m). DSC may also be used to examine the purity and composition of the polymer. The crystallinity of the present polymer compositions may range from about 0% to about 10%, about 10% to about 20%, about 20% to about 70%, about 20% to about 40%, about 30% to about 60%, or from about 40% to about 50% (all values are weight/weight (w/w)).

Wide-angle X-ray scattering (WAXS) or small-angle X-ray scattering (SAXS) may be used to determine the crystalline structure, degree of crystallinity and stereocomplexation of the polymer

In one embodiment, the sample is scanned in a wide angle X-ray goniometer, and the scattering intensity is plotted as a function of the 2Θ angle. Tsuji, Poly(lactide) Sterocomplexes, Formation, Structure, Properties, Degradation and Applications. Macro. MoI. Bio. Sci. 5:569-597 (2005).

The morphology of the present polymer may be studied by scanning electron microscopy (SEM) or transmission electron microscopy (TEM). In one embodiment, a polymer sample is sputter-coated with gold layer using a sputter-coater before mounted on the microscope. For the degradation test in vitro, the appearance of pores, cracks, channels or other similar structure may indicate the ongoing erosion of the polymer. The morphology of the present polymer may also be determined by polarized light microscopy, atomic force microscopy (AFM) or energy dispersive X-ray spectroscopy (EDS). In one embodiment, a polarizing optical microscope equipped with a heating device is used. The sample is placed on a glass plate, heated to its melting temperature (Tm), and then cooled at 10°C/min to 120⁰C.

The chemical compositions of the present polymer may be identified by Infrared (IR) or Raman spectroscopy. The chemical composition, copolymer and blend ratio and end groups of the present polymers may be studied by magnetic resonance spectroscopy (NMR). In one embodiment, ¹H-NMR spectrum of the polymer is recorded in CDCI₃. In another embodiment, ¹³C-NMR spectrum of the polymer is recorded. The inherent viscosity and molecular weight of a polymer may be determined by viscometry. The molecular weight of the present polymer may also be determined by static light scattering (SLS). The thermal stability of the present polymer may be determined by thermogravimetric analysis (TGA) and the surface chemical composition of the present polymer may be studied by X-ray photoelectron spectroscopy (XPS). The melt viscosity and stress relaxation of the present polymers may be determined by rheology.

Mechanical properties of the polymers may be assessed. For example, Tensile testing can be performed using an Instron testing machine that elongates a sample, where the force required to break the sample is recorded. This produces a stress strain curve from which mechanical properties (modulus, strength, yield and elongation at break) are measured. Compression testing can also be measured using an Instron testing machine that places a sample under a crushing load and deformation is recorded. Flexural testing may be performed using an Instron testing machine or dynamic materials analysis that places a sample in a three-point bending apparatus to record the stiffness of a material. In this assay, flexural strength and flexural modulus are recorded. Dynamic mechanical analysis (DMA) is used to measure thermal transitions and mechanical properties of polymers resulting from changes in temperature, time, frequency, force, and strain placed on a sample. Density can also be assessed by Gas Pycnometer. kLφliZviwvv_:polymathj dBbSiCpjn/rn^chardcal^hy^icaLβh^_^

Strain induced crystallization will also be examined. Uniaxial and biaxial deformations as well as the post annealing stage affect the development of structure and performance characteristics. The crystal structures and physical parameters of the polymer compositions are measured during deformation at all stages. X-ray diffraction techniques, online spectral bi-refringence techniques, real time FTIR, RAMAN spectroscopy and PET may be used to monitor crystallinity. Martins et al. Polymer 48: 2109 - 2123 (2007).

Many polymers display another type of localized yielding behavior which results in whitening of the polymer in the region of maximum deformation. Under a microscope, these localized regions of yielding display an increase in volume (dilatation) through formation of micro-cracks which are bridged by polymer fibrils. Crazing and stress whitening are the typical deformation mechanisms. Because crazing is a dilatational mechanism it is expected to occur in regions of high dilatational stress such as in the interior of thick samples or at the lateral edges of a hole cut in a sample. I. M. Ward, "Mechanical Properties of Solid Polymers, 2'nd Ed." Wiley, NY, 1983.

Degradation of the copolymers blends after extrusion or molding will also be examined. U.S. Patent No. 6,794,485. For example, a molded sample such as stent can be used directly for the biodegradation test or the blended polymer may be cut into cubes after extrusion. Any desired shape or volume may be used for the test, ranging from about 0.5 mm³ to about 1 mm³, 10 mm³ to about 100 mm³, from about 20 mm³ to about 80 mm³, or from 40 mm³ to about 60 mm³. The polymer sample is then placed in a solution to study its degradation. In one embodiment, the sample is placed in phosphate buffer solution (PBS, pH 7.4) at 37°C. The physical properties of the polymer sample may be studied for about 1 month, 2 months, 3 months, 4 months, about 6 months and 1 year. The in vitro degradation kinetics of the present bioabsorbable polymers show less than about 5% overall breakdown after storage for 1 month at physiological conditions (e.g., phosphate buffered saline at 3⁰C); in other embodiments, the overall breakdown is less than about 10%, 20%, 30% or 40% after storage for 1 month, 2 months, 3 months or 6 months at physiological conditions. The solution used for the degradation test may also be Tris-buffered saline (TBS), 4-(2- hydroxyethyl)-l-piperazineethanesulfonic acid (HEPES) buffer, 3-(N- morpholino)propanesulfonic acid (MOPS) buffer, piperazine-N,N'-bis(2-ethanesulfonic acid) (PIPES) buffer, or any other desired buffer system. The pH of the buffer may range from about 6 to about 8.5, from about 6.8 to about 8, or from 7.2 to about 7.6. The degradation test may be conducted at about 20⁰C to about 50⁰C, from about 25°C to about 45°C, about 47°C, or at about 37°C. The pH, composition and volume of the buffer system may remain the same or vary from the beginning to the end of the test period. The temperature at which the degradation test is conducted may remain the same or vary from the beginning to the end of the test period. Prior to the characterization of the polymer sample, it may be washed with distilled water and dried in a vacuum. The physical and mechanical properties of the polymer are assayed as described above. In one embodiment, the molecular weights of the polymers are measured by GPC. The degradation rates can be estimated by the mass loss (%) and molecular weight reduction (%). The polymer blend can also be examined by scanning electron microscope (SEM).

Degradation of polymers may also be examined using TOF-SIMS spectroscopy. U.S. Patent Nos. 6,864,090 and 6,670,190. By tuning the biodegradable polymers of the present invention to degrade at a specific rate, drug elution can be precisely controlled and ceases entirely with the complete degradation of the polymer.

In addition, the degradation products are assayed for immunological properties by titering their effect on (i) Leukocyte Migration, (ii) Endothelial Cell Adhesion, (iii) Integrin- Mediated Adhesion, (iv) T cell proliferation, (v) B cell proliferation, (vi) T cell activation, (vii) COX Activity Assay, (viii) cytokine activation, (ix) Arachidonic Acid cascade, (x) Matrix Metalloproteinases, (xi) Signal transduction pathway activation, e.g., EGF, (xii) Transcription Factor, e.g., NFKB, and (xiii) growth factors, e.g., TGF.

The following examples are considered to be non-limiting and only representative of selected embodiments.

Example 1

Three batches of polymer blends were prepared. The compositions of the batches are shown below in table I. Table I: Polymer Batches Compositions by Weight Percent

l. Poly-L-lactide

2. Poly-D-lactide

3. Poly-L-lactide-co-ε-capro lactone

4. Poly-L-lactide-co-TMC

5. molar ratio L-lactide to -ε-caprolactone: note these molar rations only represent nominal ratios, i.e., the standard error is +/- 5% 6. nominal molar ratio L-lactide to TMC

7. nominal molar ratio L-lactide to TMC

Differential scanning calorimetry (DSC) and Wide Angle Scattering X-ray diffraction ("WAXS" ) was done on each sample.

The polymer blends were extruded into a long, hollow tube having varying wall thicknesses. In certain cases, the tubes were cut into ringlets having a width of 1-2 mm. Before analysis, the tubes or ringlet were disposed on an annealing mandrel having an outer diameter of equal to or less than the inner diameter of the tube and annealed at a temperature between about the polymer glass transition temperature and the melting temperature of the polymer blend for a time period ranging from about five minutes to 18 hours in air, an inert atmosphere or under vacuum. In various embodiments, the time of annealing ranged from about 5 minutes to about 2 hours, about 10 minutes to about 1 hour, about 15 minutes to about 30 minutes or about 15 minutes. The temperature of annealing ranged about 6O⁰C to about 15O⁰C, from about 7O⁰C to about 14O⁰C, from 8O⁰C to about 12O⁰C. In the present example, P-11371 and P-11369 were annealed for 15 minutes at 8O⁰C and P-11228 was annealed for 15 minutes at 12O⁰C.

In several cases, the tubes or ringlets were stressed after annealing by sliding the tube or ringlet on to a tapered mandrel having an outer diameter greater than the inner diameter of the tube or ringlet. The degree of expansion ranged from about 10% (dl/d2) to about 50% (dl/d2) where dl represents staring or initial diameter and d2 represents expanded diameter.

The DSC Thermograms for the batches are shown in Figures 27 through 35, Pl 1228, P 11369 and P 11371. The DSC thermograms were produced using at TA Instrument QlO DSC. Approximately 3 mg of each material was placed in an aluminum pan and sealed. The sample pan was placed into the DSC instrument with an empty aluminum pan as its reference. The material was then heated using a ramp program from -50 to 25O⁰C at 20°C/min. The TA Software was then used the calculate the approximate T_g , T_c, and T_m, if they occurred.

Table 11: Summary of DSC Analysis

1. The T_m values represent approximate peak values with the lower value being the first or homoenatiomer crystalline structure which is melting and the upper value is the approximate peak of melting for the stereocomplex.

2. The noted values are approximate.

3. The noted values are approximate.

Figure 27, Pl 1228 untreated, presents a single strong T_g at about 64⁰C, a crystallization exotherm at about 115⁰C with a H_c of about 26.6 J/g. There are 2 distinct T_m one peak at about 179⁰C representing the homo-enantiomer crystal of poly- L or D Lactide and the other peak at about 217⁰C representing the stereocomplex of L and D. The H_c at

115⁰C does not offset the total H_m suggesting the presence of some crystallization in the raw or untreated state. However, the corresponding WAX (Figure 37) shows the untreated sample as predominately amorphous. The heat of crystallization of the stereocomplex appears to be in the same temperature range as part of the homo-enantiomer melting curve masking or offsetting the exotherm.

Figure 28, Pl 1228 annealed, presents two glass transitions at about 61⁰C and 128⁰C. The appearance of a T_g at 128⁰C suggests a complex glass transition associated with the stereocomplex and significant domain differentiation between the stereocomplex and homo- enantiomer crystals. The absence of a crystallization exotherm at about 115⁰C suggests that there is no crystallization occurring during the heating during the DSC test and that the associated dual crystal structures at 18O⁰C and 217⁰C were produced during annealing.

Figure 29, Pl 1228 annealed and stressed presents only a single T_g at about 59⁰C, and two distinct T_m one at about 179⁰C (representing the Poly-lactide homo-enantiomer crystal) and one at about 217⁰C (representing the stereocomplex crystal). The absence of the second Tg at 128⁰C (see, Figure 28) suggests strain induced reordering into crystal morphology.

The corresponding WAXS patterns for the annealed sample, see Figures 37a and b below confirms the coexistence of both the pseudo orthorhombic crystal structure of the poly- L or D-lactide homo-enantiomer crystal and the triclinic crystal of the polylactide stereocomplex as shown in the DSC (Figure 28). After stressing, see, Figures 38a and b, below continues to show both L and/or D homo-enantiomer crystal morphology along with the stereocomplex. The peak width indicates an increase in crystallinity with the introduction of stressing the sample. Figure 30, DSC for Pl 1369 untreated, presents a single T_g at about 55⁰C, a strong crystallization exotherm of about 23.7J/g at about 100⁰C, and 2 distinct melting endotherms one at about 179⁰C and at about 224⁰C with a combined H_m of about 38.5 J/g. These two melting peaks correspond to the multiple crystal morphologies of the poly-L and/or D lactide homo-enantiomer and the polylactide stereocomplex. The H_c at about 100⁰C of about 23.7J/g does not appear to account for all of the crystal structure melting in the two subsequent endotherms, suggesting either the presence of some crystallinity in the untreated sample or unaccounted crystallization exotherm in the 195⁰C region. The corresponding WAXS diffraction pattern for this sample (Figure 39) confirms that the untreated sample is predominately amorphous. Figure 31 which shows the DSC for Pl 1369 annealed, shows a single strong T_g at about 64⁰C and 2 distinct crystalline melting endotherms at about 179⁰C and 225⁰C corresponding to the poly-L and/or D lactide homo-enantiomer crystal and the polylactide stereocomplex crystal structures, respectively. The absence of the crystallization exotherm from Figure 31 at about 100⁰C suggests that the crystallization occurred during the annealing. The corresponding WAXS analysis, see, Figures 40a and b below shows the dominate crystal structure present being that of the D and/or L polylactide homo-enantiomer. This reveals that even though the DSC shows the stereocomplex in this sample, the formation of the stereocomplex appears to be suppressed at this annealing condition and is predominately formed during the DSC heating cycle.

Figure 32, DSC for Pl 1369 annealed and stressed, shows a single T_gat about 63⁰C and two strong crystalline melting endotherms at about 178⁰C and 223⁰C representing the poly L and/or D lactide homo-enantiomer and poly-lactide stereocomplex crystal morphologies. The corresponding WAXS analysis, see, Figures 41a and b below, shows wider peaks representing an increase in degree of crystallization due to the applied stress. Further, the strain induced crystal morphology appears to remain unchanged from the unstressed sample.

Figure 33 shows the DSC for Pl 1371 untreated. This DSC presents a strong T_g at about 59⁰C, and what appears to be a weak transition at below O⁰C suggesting a small degree of immiscibility. A significant crystallization exotherm of about 25J/g presents at about 106⁰C. Two crystalline melting endotherms at about 179⁰C and 22O⁰C represent the poly L and/or D lactide homo-enantiomer and polylactide stereocomplex crystal structures with a total H_m of about 35.7 J/g suggests the presence of some crystallinity in the untreated sample or unaccounted for crystallization exotherm for the stereocomplex at about 19O⁰C. The corresponding WAXS diffraction pattern for this sample (see, Figure 42 below) confirms that the untreated sample is predominated amorphous.

Figure 34 shows the DSC for Pl 1371 annealed. This DSC presents a single T_g at about 6O⁰C, a small crystallization exotherm of about 5.6 J/g at about 105⁰C, and two distinct crystalline melting endotherms at about 178⁰C and about 22O⁰C with a combined Hm of about 41.97J/g. The presence of the crystallization exotherm suggests that this annealing condition for this formulation leaves polymer that may be crystallized during the heat ramp cycle of the DSC, that is, remains available for further crystallization. The corresponding WAXS data, see, Figures 43 a and b, WAXS for Pl 1371 annealed show predominately the crystal morphology of the poly L and/or D polylactide homo-enantiomer. This reveals that even though the DSC shows the stereocomplex in this sample, the formation of the stereocomplex appears to be suppressed at this annealing condition and is predominately formed during the DSC heating cycle.

Figure 35 shows the DSC for P-11371 annealed and stressed. This DSC presents a T_g at about 58⁰C, a small crystallization exotherm of about 4.1J/g at about 103⁰C, and two distinct crystalline melting endotherms at about 177⁰C and about 22O⁰C representing both the poly L and/or D lactide homo-enantiomer crystal as well as the poly-lactide stereocomplex. The somewhat smaller heat of crystallization presented in this DSC versus that of Figure 34 suggests crystallization induced by the stress applied to the sample. The samples were analyzed by x-ray diffraction. XRPD patterns were collected using a Bruker D-8 Discover diffractometer and Bruker's General Detector System (GADDS, v. 4.1.20). An incident micro-beam of Cu Ka radiation was produced using a fine-focus tube (40 kV, 40 mA), a Gόbel mirror, and a 0.5 mm double-pinhole collimator. The incident X-ray optics are effectively "parallel beam". With the use of an area detector system, there are no secondary X-ray optics between the sample and detector. Prior to the sample measurement, a silicon standard (NIST SRM 640c) was analyzed to verify the Si 111 peak position.

A specimen of the sample was supported using a capillary and secured to a translation stage. A video camera and laser were used to position the area of interest to intersect the incident X-ray beam in reflection geometry. When allowed by the sample geometry, some rocking of the sample was used during data collection to optimize orientation statistics. A beam-stop was positioned close to minimize air scatter from the incident beam.

Diffraction patterns were collected using a Hi-Star area detector located 15 cm from the sample and processed using GADDS. The detector and incident X-ray beam are not moved during the active data collection period and the area detector returns a 2D image of the powder diffraction rings produced by the sample. The intensity in the GADDS image of the diffraction pattern was integrated using a step size of 0.04° 2Θ over the range 2.0 to 37.6° 2Θ. The integrated patterns display diffraction intensity as a function of 2Θ. The absolute error in 2Θ (x-axis) is about +/- 0.2 degrees, while the relative error (peak to peak differentiation) is about +/- 0.02. The error in the peak intensity is about 5% (see, H. P. Klug and L.E. Alexander: X-ray Diffraction Procedures For Polycrystalline and Amorphous Materials: Wiley-Interscience Publication, 1974 (second edition)). Table III presents the WAXS data. Table III: WAXS Analysis Summary

Figure 42 shows the X-ray powder diffraction pattern taken from an intact tube of raw or unprocessed material (Pl 1371). The sample appeared amorphous, i.e., no crystallinity was observed for this sample. The sensitivity of the WAXS machine is capable of detecting 1% or greater crystalline material in the sample. Amorphous material indicates that overall crystallinity was less than about 95% (w/w), less than about 98% (w/w) or less than about 99% (w/w). Figures 43 a and b (diffraction peaks identified) shows the X-ray powder diffraction pattern taken from an intact annealed tube of material (P 11371). A large crystalline response on an amorphous halo corresponding to about 23.4% crystallinity was observed. The width of the main crystalline peak (pseudo Voight) is about 0.352 degrees.

Figures 44 a and b (diffraction peaks identified) shows the X-ray powder diffraction pattern taken from intact ringlet material that was annealed and stressed (P 11371). Stressing was caused by sliding material over a tapered mandrel, similar to that seen in the DSC data. A large crystalline response on an amorphous halo corresponding to about 36.5% crystallinity was observed. The width of the main crystalline peak (pseudo Voight) is about 0.418 degrees.

Figure 39 shows the X-ray powder diffraction pattern taken from an intact tube of raw or unprocessed material (Pl 1369). The X-ray powder diffraction pattern is predominately amorphous with a small crystalline peak at 16.5 2Θ corresponding to about 1.0% crystallinity was observed. Figures 40 a and b (diffraction peaks identified) show the X-ray powder diffraction pattern taken from an intact annealed tube of material (Pl 1369). A large crystalline response on an amorphous halo corresponding to about 29.5% crystallinity was observed. The width of the main crystalline peak (pseudo Voight) is about 0.367 degrees. The width of the main crystalline peak (pseudo Voight) is about 0.352 degrees.

Figures 41 a and b (diffraction peaks identified) show the X-ray powder diffraction pattern taken from intact, ringlet material that was annealed and stressed (Pl 1369). A large crystalline response on an amorphous halo corresponding to about 35.7% crystalline was observed. The width of the main crystalline peak (pseudo Voight) is about 0.388 degrees.

Figures 36, 37 a and b (diffraction peaks identified) and 38 a and b (diffraction peaks identified) show the WAXS pattern for Batch Pl 1228 under the conditions noted in the figures. Both the WAXS and corresponding DSC patterns show the presence of psuedo orthorhombic-crystals of the polyL or D-lactide homo-enantiomer crystals together with triclinic crystals of the lactide sterocomplex. Table IV summarizes the percent crystallinity in each particular state for the two batches, Pl 1369 and Pl 1371.

Table IV - Percent Crystallinity

Table IV shows the peak width for the various samples under several different conditions. Crystalline diffraction peak widths are good measure of the kinetic perfection of a crystalline material and can be used to characterize a materials micro-structure in terms of the size of perfect crystalline regions and micro-strain between the crystalline regions. Lanford et al, Powder Diffraction. Rep. Prog. Phys. 59:131-234 (1996).

Table V - Peak Width

Batches, Pl 1369 and Pl 1371, were also tested for tensile strength and ductility. Tensile strength is the stress at the maximum on the engineering stress-strain curve and ductility is the measure of the degree of plastic deformation that has been sustained at fracture and can be expressed quantitatively as percent elongation, %EL = (lf-10/10) x 100.

The tests were conducted as follows. A United Pull Test Fixture, Model # SSTM-I. United 51b Load Cell, Model # 5LB T was used. The samples cut into 1-2 mm sections and then loaded on 'U' shaped test wires, with the sections fixed between an upper clamp an lower clamp. The samples were lowered into a water bath at physiological temperatures and pulled for various times at about 4.7"/min. After pulling the samples were removed from the clamps and measured on a calibrated Micro-Vu. Figures 45a and b show the results of the elongation analysis and Figure 46a and b the tensile or pull strength. The mean percent elongation for untreated Pl 1369 is 186% +/- 49%, while the mean percent elongation for Pl 1369 which had been annealed at 8O⁰C for 15 minutes is 93% +/- 67%; the mean percent elongation for untreated Pl 1371 is 163% +/- 46%, while the mean percent elongation for Pl 1371 which had been at 8O⁰C for 15 minutes is 23% +/- 16%. The mean tensile strength for untreated Pl 1369 is 43.81 +/- 8.6 (units are MegaPascals "MPa"), while the mean tensile strength for Pl 1369 which had been annealed at 8O⁰C for 15 minutes is 54.88 +/- 10.97 MPa; the mean tensile strength for untreated Pl 1371 is 37.89 +/- 5.44 MPa, while the mean tensile strength for Pl 1371 which had been at 8O⁰C for 15 minutes is 44.88 +/- 1.62 MPa.

The embodiments illustrated and discussed in this specification are intended only to teach those skilled in the art the best way known to the inventors to make and use the invention. Nothing in this specification should be considered as limiting the scope of the present invention. Modifications and variation of the above-described embodiments of the invention are possible without departing from the invention, as appreciated by those skilled in the art in light of the above teachings. It is therefore understood that, within the scope of the claims and their equivalents, the invention may be practiced otherwise than as specifically described.

All patents, applications, publications, test methods, literature, and other materials cited herein are hereby incorporated by reference.

Claims

What is claimed is:

1. A stent comprising a blend formed from poly-L-lactide, poly-D-lactide or mixtures thereof and a copolymer moiety comprising poly-L-lactide or poly-D-lactide linked with ε- caprolactone or trimethylcarbonate wherein, the poly-L-lactide or poly-D-lactide sequence in the copolymer moiety is random with respect to the distribution of ε-caprolactone or trimethylcarbonate and where the wide-angle X-ray scattering (WAXS) exhibits 2Θ values of about 16.48 and about 18.76.

2. The stent of claim 1 wherein the co-polymer moiety comprises poly-L-lactide or poly- D-lactide linked with ε-caprolactone.

3. The stent of claim 2 wherein the polymer moiety comprises poly-L-lactide.

4. The stent of claim 2 wherein the polymer moiety comprises poly-D-lactide.

5. The stent of claim 1 wherein the co-polymer moiety is poly-L-lactide or poly-D- lactide linked with TMC and the molecular weight of the co-polymer ranges from about 1.2 IV to about 2.6 IV.

6. The stent of claim 2 wherein the molecular weight of the co-polymer ranges from about 0.8 to about 6.0.

7. The stent of claim 1 wherein the WAXS 2Θ values further comprise peaks at about 11.92, about 20.66, about 22.24 and about 28.84.

8. The stent of claim 1 comprising a blend having about 20% - 45% (w/w) poly-L- lactide, about 35% (w/w) to about 50% (w/w) poly-D-lactide and about 10% (w/w) to about 35% (w/w) poly L-lactide-co-TMC or poly-L-lactide- ε-caprolactone.

9. The stent of claim 1 wherein the poly-L-lactide or poly-D-lactide ranges from about 20% (w/w) to about 95% (w/w).

10. The stent of claim 9 wherein the poly-L-lactide or poly-D-lactide ranges from about 50% (w/w) to about 95% (w/w).

11. The stent of claim 10 wherein the poly-L-lactide ranges from about 60% (w/w) to about 95% (w/w).

12. The stent of claim 11 wherein the poly-L-lactide ranges from about 70% (w/w) to about 80% (w/w).

13. The stent of claim 1 wherein greater than 7 L-lactides or D-lactides are arrayed sequentially in the copolymer moiety.

14. A stent comprising a blend formed from poly-L-lactide, poly-D-lactide or mixtures thereof and a copolymer moiety comprising poly-L-lactide or poly-D-lactide linked with ε- caprolactone or trimethylcarbonate wherein, the poly-L-lactide or poly-D-lactide sequence in the copolymer moiety is random with respect to the distribution of ε-caprolactone or trimethylcarbonate, wherein there is at least about 95% (w/w) amorphous material in the stent.

15. The stent of claim 14 wherein there is at least about 98% (w/w) amorphous material.

16. The stent of claim 15 wherein there is at least about 99% (w/w) amorphous material.

17. The stent of claim 1 wherein percent crystallinity ranges from about 0% (w/w) to about 10% (w/w).

18. The stent of claim 1 wherein the percent crystallinity ranges from about 20% (w/w) to about 70% (w/w).

19. The stent of claim 18 wherein the percent crystallinity ranges from about 30% (w/w) to about 60% (w/w).

20. The stent of claim 19 wherein the percent crystallinity ranges from about 30% (w/w) to about 60% (w/w).

21. A stent comprising a blend formed from poly-L-lactide, poly-D-lactide or mixtures thereof and a copolymer moiety comprising poly-L-lactide or poly-D-lactide linked with ε- caprolactone or trimethylcarbonate wherein, the poly-L-lactide or poly-D-lactide sequence in the copolymer moiety is random with respect to the distribution of ε-caprolactone or trimethylcarbonate and where the wide-angle X-ray scattering (WAXS) exhibits 2Θ values of about 16.65 and about 18.96.

22. The stent of claim 21 wherein the WAXS 2Θ values further comprise about 12.00, about 14.80, about 20.67, about 22.35, about 23.92, about 24.92, about 29.16 and about 31.28.

23. The stent of claim 1 wherein the T_m peaks occur at about 18O⁰C and about 217⁰C.

24. The stent of claim 21 wherein the T_m peaks occur at about 178⁰C and about 22O⁰C.

25. The stent of claim 21 wherein about T_g is 61⁰C and about 128⁰C.